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ABSTRACT 
CORRELATION OF CLINICAL, RADIOLOGICAL, MICROBIOLOGICAL 
FEATURES AND DRUG RESISTANCE PATTERN OF MYCOBACTERIUM 
TUBERCULOSIS IN PATIENTS WITH HIV TUBERCULOSIS CO-
INFECTION 
INTRODUCTION 
 Drug Resistant Tuberculosis is a major challenge in tuberculosis high 
prevalent  countries. This challenge becomes bigger where HIV TB coinfection 
is present. 24.6% of TB deaths occur among HIV positive cases. 
AIM 
To determine the correlation between clinical, radiological, 
microbiological features and the drug resistance pattern of Mycobacterium 
tuberculosis in patients with HIV tuberculosis co infection. 
OBJECTIVES 
1. To determine the relationship between clinical presentation of HIV -
pulmonary tuberculosis co infection and drug resistance pattern. 
2. Compare each of the variables CD4 count, HIV staging, chest Xray 
features, sputum smear for AFB, LPA with drug resistance pattern. 
3. Prevalence of MDR-TB in HIV TB co-infection.  
MATERIALS & METHODS 
 It is a prospective study done at Government Hospital of Thoracic 
medicine, during April 2013 to March 2014. 
Inclusion Criteria : All HIV seropositive patients with pulmonary TB, 
Age > 18 years 
Exclusion Criteria:  HIV patients with only extrapulmonary TB, Age < 
18 years, Patients who are moribund, sick and unable to produce sputum, 
Patients who are not willing to participate in the study, Patients whose sputum 
showed no growth in LJ culture medium. 
Collection of clinical samples/ data:  Symptoms duration, HIV diagnosis 
and treatment history, Antituberculous treatment history, Height & Weight,  
Chest radiograph, Sputum for AFB staining, LPA, sputum Mtb culture, CD4 
count. Allotting score for each of the variable. Predict MDR based on score. 
Comparing prediction with sensitivity results and analyse. 
Features/score 0 1 2 
Contact H/o PT absent   present 
H/O ATT No   Yes 
HIV STAGE 4 No Yes   
CD4 count >200 <200   
BMI >18 <18   
Pulmonary TB alone with dissemination   
chest xray no cavity cavitation   
sputum smear negative positive   
 
OBSERVATION & RESULTS 
 230 patients were included in the study - 198 were male, 32 female. Mean 
age 39.5. totally 5.2% cases were MDR, 4.8% monoresistant to Rifampicin (R). 
Among  new case, MDR 3.4%, monoresistants to R 2.7%. Among retreatment 
cases, MDR was  8.5% and monoresistant to R  8.5%. Odds ratio was 3.18 
(95% CI 1.31 -  7.71) when Rif resistance is compared with TB case. 10% of 
disseminated TB cases are MDR. Association between disseminated TB & Rif  
Resistance is odds ratio of 2.71 (95% CI 1.07 – 6.09) P value of 0.56 (> 0.05) is 
obtained when symptoms duration is compared with rifampicin resistance. CD4 
count compared with MDR - TB gives odds ratio of 7.30 (95% CI 0.92 – 57.71). 
Odds ratio is 2.59 (95% CI 1.08 – 6.03) where HIV stage is compared with 
rifampicin resistance. Drug sensitivity  of 154 cases were obtained by LPA, rest 
were obtained by culture. 67% of MDR cases were detected using LPA. Odd’s 
ratio is 2.96 (95% CI 1.23 – 7.12) when score more than 4 compared with 
Rifampicin resistance. 
CONCLUSION 
In  summary,  prevalence  of  MDR  TB  in  this  study  is  2.2%  in  
new cases and 8.5% in retreatment cases. Prevalence of Rifampicin 
resistance in new cases is 6.1% and that in retreatment cases is 19%.  
History of prior treatment of tuberculosis, HIV stage 4, 
disseminated TB were significantly associated with rifampicin 
resistance. 
In this study, CD4 count less than 200 was significantly 
associated with MDR TB and drug resistant TB. 
HIV treatment was not associated with drug resistance pattern. 
Duration of symptoms did not affect prevalence of MDR TB. There 
was no significant association between chest x ray lesions, cavitation 
with MDR TB. Sputum smear status had no significant relation with 
MDR TB. 
 Sensitivity of line probe assay in this study is 67%. 
Scoring with 8 variables with score more than 4 was 
significantly associated with Rifampicin resistance. Since the study 
population is small, further studies with large study population will be 
helpful in validating this score. 
Keywords 
HIV, Tuberculosis, Drug Resistance,  Line Probe Assay. 
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INTRODUCTION 
              Drug resistant tuberculosis is the biggest challenge in 
tuberculosis high prevalent countries. In 2012, there were an 
approximately 8.6 million incident tuberculosis(TB) cases and 1.3 
million people lost their lives due to the disease1. Among these 1.3 
million deaths, 3,20,000 were among people who were human 
immunodeficiency virus (HIV) positive1. Thus 24.6% of TB deaths 
occurred among HIV positive cases. 
 
   TB deaths in world 
 
  Among these deaths, 1,70,000 deaths were due to 
multidrug resistant tuberculosis(MDR TB). Thus 13% of deaths is due 
to MDR TB globally1. This is relatively high when compared with 
4,50,000 incident cases of MDR TB annually. 
2 
Indian Scenario 
 In 2012, there was an estimated 2.2 million incident TB cases in 
India1. This shows that India has the lion’s share of global TB cases 
amounting to 26% of total cases.  
3,10,000  people died due to TB in India in 20121. 42,000 deaths 
among these occurred in HIV positive individuals. Estimated prevalence 
of HIV among TB patients in India is 5.95%3. 
 Drug Resistance Surveillance studies have estimated the 
prevalence of MDR-TB to be about 2.2% in new cases and 15% in re-
treatment cases1. 
HIV-TB co infection is another massive challenge to TB control 
in resource limited countries. There exists a synergetic relationship 
between tuberculosis (TB) infection andHIV infection which results in 
arise in their prevalence, morbidity and mortality2. This co-infection is a 
huge public health problem that is ominous as a potential pandemic. 
This should be of serious concern and spur emergency action to control 
and reduce these infections.  
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The interaction between TB and HIV is as follows: 
In HIV: 
• TB is a most important co-infection2; 
• TB infects both HIV-infected and non-infected persons; 
• TB is the leading cause of mortality in HIV patients2; 
• TB causes serious illness and accelerates progression to AIDS. 
In TB: 
• HIV is the main risk factor for progression from latent TB infection to 
active disease2; 
•HIV increases the risk of recurrent TB2. 
• HIV leads to increase in TB incidence; 
• HIV gives rise to hot spots of TB transmission2; 
• HIV causes increase in morbidity in TB patients because of 
HIVrelateddiseases2; 
• HIV elevates the adverse drug reactions to TB treatment2; 
• HIV raises TB case fatality rates; 
As the patient becomes severely immunosuppressed with the 
advancement of disease, the presentation is more likely to be extra-
pulmonary or smear-negative than in HIV-uninfected TB patients4. This 
faces a major challenge in diagnosis and result in misdiagnosis or delays 
in diagnosis4, and therefore, higher morbidity and mortality due to HIV 
4 
TB co-infection. In such scenarios, when diagnosing TB becomes 
difficult, diagnosing drug resistant TB becomes much more difficult.  
This study helps in identifying predictors of MDR TB in HIV patients, 
thus helping in early diagnosis of MDR TB in HIV patients. 
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Risk of TB in HIV patients 
 HIV patients have increased risk of acquiring tuberculosis. Life 
time risk of tuberculosis in non HIV individuals with latent TB infection 
is 10%.For HIV-infected individuals with latent TB infection, the annual 
risk of developing active TB reaches 5–10%6 and lifetime risk increases 
to 60%. 
 
 
  
 
 
 
HIV patients are more prone to  
x Develop active TB, once infected. 
x Relapse TB after completing treatment. 
x Acquire re-infection with another strain of TB bacilli 
x Increased mortality 
Prevalence of HIV in TB patients in India is 5.95%3. 
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Pathogenesis of TB 
 The pathogenesis of tuberculosis depends on the cellular 
immunity of the host. This cellular immunity is responsible for the 
resistance to bacteria and also for the hypersensitivity to tubercular 
antigens7. Alveolar macrophages are the primary cells infected by the 
bacilli. During early phase of infection, bacilli proliferate in 
macrophages and during late phase, macrophages are stimulated by Th1 
response to contain the infection. 
 TB bacilli enter macrophages by endocytosis, by binding to 
mannose receptors7.  Mycobacteria multiply within the macrophages by 
blocking phagolysosome formation. Several mechanisms involved in 
this are inhibition of calcium channels and blocking assembly of 
proteins required for phagosome and lysosome fusion. Bacilli enter the 
blood stream and seeding at multiple sites occurs. Patient is 
asymptomatic at this stage. 
 After 3 weeks, antigen presenting cells in the lymph nodes, are 
activated by mycobacterial antigens. These cells stimulate Th1 cells by 
releasing IL-12. Mature Th1 cells in lungs and node produce Interferon –
gamma7 (IFN –Ȗ). IFN –Ȗ plays a major role in activating macrophages 
by stimulating the formation of phagolysosome. Phagolysosome creates 
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an acidic environment which is inhospitable to bacilli. IFN –Ȗ stimulates 
macrophages to release iNOS7. iNOS releases nitric oxide. Nitric oxide 
releases reactive nitrogen species and also promotes release of oxygen 
free radicals. These free radicals promote destruction of mycobacterial 
constituents. 
 IFN –Ȗ plays main role in formation of granuloma. IFN –Ȗ 
activates macrophages. They release tumor necrosis factor (TNF). TNF 
recruits monocytes which differentiate into epitheloid histiocytes7. 
Epitheloid cells helps in the formation of granuloma. This characteristic 
granuloma formation is absent in HIV patients. 
Th1 cells has major role in containing the disease. Any defect in 
Th1 response, thus leads to absence of resistance and disease 
progression. 
TB Reactivation by HIV  
 The depletion of CD4+T cells is a significant contributor to the 
increased risk of reactivation of latent TB and susceptibility to new M. 
tuberculosisinfection6. CD8+T cells have a role in the control of latent 
TB6. M. tuberculosis infection is rampant in patients with HIV are  due 
to deregulated chemotaxis, HIV manipulation of macrophage 
bactericidal pathways8, up-regulation of M. tuberculosis entry receptors 
9 
on macrophages9 , and a tipped Th1/Th2 balance . HIV attenuates tumor 
necrosis factor (TNF)-mediated macrophage apoptotic response to M. 
tuberculosis and thus promotes bacterialsurvival10. 
 An alteration of the level of the protective adaptive immune 
responses facilitates reactivation of TB infection8. Several immune 
mechanisms, such as increased production of IL-2711,  TGF-b  ,  PGE-2,  
SOCS1, or the decoy receptor D6 or decreased levels of TNF, IFN-c, 
and polyfunctional specific T cells, are considered to play a significant 
role in such reactivation8. Factors like IL-27down-regulate the IFN-c/IL-
12 axis thus weakening bacterial control8.  D6 decoy receptor suppress 
efficient bacterial clearance.  
Granulomas are the hallmark of TB’s pathology. Mycobacteria 
are contained in the granuloma, which localizes infection and thus 
efficiently preventing dissemination of the bacilli between hosts8. This 
contributes to protection. TNFandCD4+cells are imperative in 
preserving granuloma organization. Formation of granuloma may fail in 
people with immunocompromised state. TB patients with AIDS have a 
dominant granulocytic infiltrate and necrosis8. They are devoid of the 
caseous necrosis present in non-HIV-infected patients with TB 
granulomas8. This is due to depletion of CD4+cells in the granuloma. 
This leads to a direct disruption of structure of granuloma and 
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obliteration of the containment of bacilli. In HIV-infected patients it can 
be a disseminated disease affecting multiple organs that are devoid of 
well-definedgranulomas8. All types of extrapulmonary TB have been 
reported in HIV infected patients. 
Features of Immune Response to HIV Infection 
The depletion of CD4+T cells is the hallmark of HIV infection8. 
Various factors are implicated in progression of HIV disease : 
x Depletion  of  the  effector  memory  CD4+T  cells  present  in  
the gut mucosa8. 
x Depletion of CD4+ cells. 
x Systemic and chronic state of immune activation8 
x Accelerated T cell turnover 
x Hyper-responsiveness of plasmacytoid DCs during the 
initial infection8 
x Increased gut permeability causing microbial translocation. 
T cell immunoglobulin mucin 3 (Tim-3) and Programmed Death 
1 (PD-1) are few of the markers of T cell exhaustion in HIV-1+patients8. 
They are released by constant antigenic stimulation. Both molecules 
promote the down regulation of host immune responses8. They help in 
sustaining T cell tolerance. Tim-3 is up-regulated in virus-specific 
CD8+T cells in chronic progressive HIV infected patients14;  Tim-3  is  
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up-regulated in antigen-specific CD8+Tcells in patients suffering from 
active TB15. This indicates that similar inhibitory receptor/ligand 
interactions play a major role in regulating host immunity to both M. 
tuberculosis and HIV infections in humans.  
Manifestations of TB in HIV patients 
 TB presentation in HIV patients differs depending on the level of 
immunosuppression. 
Early phase of immunosuppression 
x Tuberculosis presents as post primary TB  
x Sputum smear is positive for Acid fast bacilli18. 
x Chest x-ray often shows cavities. 
Late phase of immunosuppression  
x  Usually resembles primary TB 
x Usually smear negative 
x Chest x-ray shows atypical presentations like mid and lower lung 
field lesions, infrequent cavities, intra thoracic lymph nodes. 
x Mycobacteremia and extrapulmonary tuberculosis. 
% of Sputum smear positivity in pulmonary tuberculosis 
x HIV negative – 60% 
x Early HIV       - 50 % 
x Late HIV      - 30% 
12 
 
• In early phase of Immunosuppression, cavities are part of 
manifestations of pulmonary TB and so 50% of patients will have 
Sputum Smear positive results. However, inHIV patients sputum 
smear positivity rate will be less, compared with HIVnegative 
patients. 
• In late phase, though there is increased bacterial load, sputum 
smear negativity is frequent . This is due the absence of bronchial 
wall destruction because of reduced T cell mediated 
hypersensitivity resulting in expectoration of fewer bacilli in 
sputum7. Cavity formationis also less frequent. 
 
Mycobacteremia in HIV 
  Mycobacteremia is presence of mycobacteria in blood 
stream. This occurs when CD4 count falls below 200. This is because of 
fall in immunity leading to breakdown of granuloma that had contained 
the bacilli in localized sites. Moreover granuloma formation is affected 
when the immunity is lowered. This leads to spread of bacilli in blood to 
various sites. It causes seeding of bacilli in various organs which then 
manifests as disseminated TB and extrapulmonary TB.  
13 
 The extent of immunosuppression determines the frequency of 
extrapulmonary involvement7. Frequency is 10 to 15% in mildly 
immunosuppressed7 cases  whereas  it  raises  to  an  alarming  50%  in  
severely immunosuppressed individuals. 
 Extrapulmonary sites frequently affected are lymph nodes, central 
nervous system (meningeal and parenchymal), bone marrow, soft tissue, 
liver and other visceral organs. 
  Lymphadenopathy is a common presentation in HIV 
cases19. It may be due to various causes like primary HIV adenopathy, 
TB lymphadenitis, Non tuberculous mycobacteria, nodal lymphoma, 
nodal Kaposi Sarcoma. It is more common in males in HIV positive 
cases. In addition to cervical nodes, there is increased incidence of 
axillary and inguinal nodes in HIV patients when compared to HIV 
negative cases. In HIV negative cases, nodes are usually unifocal and 
they do not have extranodal disease. Frequency of multiple site 
involvement is more in HIV patients. Granuloma formation is less in 
these nodes19. They are more prone to suppuration and abscess 
formation. In contrary to sputum which is paucibacillary, pus from these 
abscess usually contain plenty of bacilli. Nodal TB can also present as a 
manifestation of Immune reconstitution inflammatory syndrome. 
14 
  HIV patients are at an increased risk of developing central 
nervous system tuberculosis including tuberculous meningitis and 
tuberculoma19. The presentation, CSF findings of TB meningitis are 
usually similar to that in HIV seronegative patients. But sometimes CSF 
findings can be normal. In such cases radiographic findings come to aid 
in diagnosis of TB meningitis. They are cisternal enhancement, basal 
ganglia infarction, multiloculated abscesses and communicating 
hydrocephalus19. Extrameningeal TB is also more common in HIV 
cases. Tuberculoma is seen in 50% of cases with TB meningitis. 
Neurological tuberculosis has been initial presentation in a quite a 
number of few cases. 
  Several hematological manifestations are seen in HIV TB 
co-infected cases. This is mainly due to bone marrow infiltration. 
Granulomas are present in bone marrow. They are different from classic 
granuloma as they are surrounded by polmorphonuclear cells and 
macrophages instead of lymphocytes. These granulomas have abundant 
bacilli. In many cases bone marrow aspirate has helped in diagnosing 
TB in high prevalent countries like India. 
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Exacerbation of HIV Infection by M. tuberculosis infection 
 The mortality and incidence rates are higher for new AIDS-
defining opportunistic infections if the individuals are co-infected with 
HIV &TB. M.tuberculosis infection has a negative effect on the immune 
response to HIV and on progression to AIDS8.HIV and TB bacilli, both 
modulates the action of macrophages and dendritic cells. Replication of 
HIV is increased locally at sites which are affected by TB bacilli in 
lungs, pleura and lymph nodes. M.tuberculosis up-regulates HIV 
replication in acutely and chronically infected T cells or macrophages, 
and also ex vivo in alveolar macrophages and lymphocytes from HIV 
patients16,17. These findings are also substantiated in real time because 
plasma viral loads are increased in HIV patients when they are suffering 
from active tuberculosis. 
Clinical screening algorithms:  
The WHO recommends that screening for TB should be done at 
the time of diagnosis of HIV in patients. Screening must also be done 
before starting antiretroviral therapy and during follow up. 
In 2007, WHO released new guidelines to help in the diagnosis of 
TB in HIV infected individuals20. This committee recommended that 
screening for TB must include asking questions about a group of 
symptoms like presence of current cough, night sweats, fever or weight 
16 
loss rather than chronic cough alone6. Sensitivity of this rule was shown 
to be 79 per cent with 50 per cent specificity. Sensitivity was 90% in 
clinical settings. The main change to existing practice will be the 
replacement of chronic cough by current cough as screening question 
and also adding of other symptoms to routine screening20. This 
screening tool can be used in ART centres to identify TB patients20. 
They must be subjected to further investigations for confirming the 
disease. 
Radiographic findings:  
Chest xray when used along with symptoms helps in identifying 
more number of TB cases. But a normal chest x-ray does not rule out the 
possibility of TB in HIV patients because upto 14% of patients may 
have normal xray. These patients can be identified using nucleic acid 
amplification tests orsputum culture for diagnosingTB. 
 
Sputum smear microscopy:  
Microscopic examination ofsputum for acid-fast bacilli (AFB) is 
most commoly used for diagnosing TB. They are cheap, easy to perform 
and mostly specific. For a specimen to be smear positive, it must contain 
approximately 105bacilli permilliliter22. Sensitivity of sputum 
microscopy in HIV cases varies from 43 to 51 per cent21.Techniques that 
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boost the sensitivity are fluorescence microscopy, specimen processing 
methods, like concentration, bleach sedimentation and same-day sputum 
collection methods23-25. Light-emitting diode(LED) bulbs reduce  the 
cost of fluorescence microscopes. This helps in widespread use of 
fluorescent microscopes. 
However, in resource limited settings, only sputum smear 
examination is routinely done for screening TB. This leads to delay in 
diagnosis of smear negative pulmonary TB cases in HIV patients. The 
drug susceptibility cannot be found by smear microscopy is also a major 
drawback. 
Growth based detection:  
Culture of Mycobacterium tuberculosis is  more sensitive than 
sputum smear. It is recommended to help in the diagnosis of TB in HIV-
infected cases26.Culture can be used for strain characterization or drug 
susceptibility testing. The solid medium like the Lowenstein-Jenson (L-
J) medium is slow, because growth of culture takes 6-8 weeks20. This 
leads to delayed initiation of treatment, which leads to adverse outcome 
of HIV TB co-infected individuals. Liquid culture mediums detect 
growth of mycobacteria in less than 1-2wk by fluorescent sensors 
[BACTEC Mycobacteria Growth Indicator Tube 960];bacterial carbon 
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dioxide production or oxygen consumption with radiometric sensors 
(BACTEC 460TB)20. 
Microscopic observation drug susceptibility (MODS) 
It is used for detection of microcolonies, cord formation and also 
for early detection of drug resistance20.It has higher sensitivity, less time 
to culture positivity. 
Molecular techniques:  
Nucleic acid amplification testing (NAAT) has high specificity, 
but its sensitivity is variable. Simplified versions of NAAT kits include 
fluorescence in-situ hybridization (FISH) loop-mediated isothermal 
amplification (LAMP) and line probe assays (LPA). 
LPA has high sensitivity (>95%) and specificity (100%) when 
culture isolates were used27. It detects both  M. tuberculosis complex as 
well as isoniazid resistance28 by inh gene, katG gene and rifampicin 
resistance by rpoB gene from early positive growth on culture or on 
smear-positive sputum. Processing by LPA involves four steps. First, 
bacterial  DNA  is  extracted  from  the  specimen.  Second,  resistance  
determining genes are amplified by polymerase chain reactions (PCR) 
using specific primers. Third, these products from PCR are hybridized 
with oligonucleotide probes (that are immobilized on a strip). Finally, 
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the captured labeled hybrids are detected using colorimeter. Results 
obtained within 48 – 72 hours. 
GeneXpert-Rif:  
WHO has endorsed the use of GeneXpert-Rif for the rapid 
diagnosis of TB as well as rifampicin resistance among HIV-infected 
patients with clinical suspicion of TB29. It is a TB-specific automated, 
cartridge-based nucleic acid amplification assay, which has fully 
automated and integrated sample preparation, amplification and 
detection using real-time PCR. It provides results within100 minutes.  
Sensitivity of a single Xpert MTB/RIF test in smear-negative/culture 
positive patients was 72.5 per cent which increased to90.2 per cent when 
three samples were tested20. XpertMTB/RIF specificity was 99 per cent. 
Xpert MTB/RIF detected rifampicin resistance with 99.1% sensitivity 
and excluded resistance with 100 per cent specificity30, 31.  This  test  has 
the potential to change the current reference standard of TB 
diagnostics20.  
Tuberculin skin test20:  
Tuberculin skin test positivity provides evidence of TB infection. 
Many HIV infected patients have a negative skin test in spite of TB 
infection or disease, due to anergy.  
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Tuberculin skin test underestimates the prevalence of latent 
tuberculosis in endemic countries. The test is neither useful to rule in 
disease nor in high TB prevalence settings to identify eligible 
individuals for prophylaxis. 
Other diagnostic techniques 
(i). Interferon-Ȗ release assay20 (IGRA):  This  test  is  used  to  
diagnose latent TB infection and is mainly useful in profoundly ill 
patients and those with severe malnutrition. There two in vitro tests to 
detect latent tuberculosis are: QuantiFERON- TB Gold and the T SPOT-
TB test. 
Both use an enzyme- linked immunospot assay to quantify the number 
of peripheral blood mononuclear cells producing IFN- Ȗ in response to 
tuberculosis specific antigen stimulation (ESAT-6 and CFP10).They are 
more expensive. IFN-Ȗ assays do not differentiate between latent and 
active tuberculosis or between immune reconstitution inflammatory 
syndrome (IRIS) and failure. WHO recommended against the use of 
IGRAs for diagnosis of active or latent TB, in resource limited settings. 
(ii) Volatile organic compounds20 (VOCs): 
These compounds released by TB bacilli in urine or exhaled air 
over sputum or bacterial culture, are calculated using sensors or gas 
chromatography–mass spectroscopy. It has been identified that infection 
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with TB produces a distinct pattern of certain VOCs when compared to 
healthy individuals. Identification of these patterns helps in creating a 
portable “electronic nose” which could sniff urine samples rapidly to 
diagnose TB. 
Management of HIV-TB co-infected patients 
 It includes various aspects of treating the patients 
 Anti-TB drugs should be given 
 Evaluation for other opportunistic infections to be done. 
 Cotrimoxazole prophylaxis to be given to all cases HIV TB co-
infection 
 Appropriate nutrition ensured for all patients 
 All family members to be screened for HIV and TB infection 
 ART to be initiated for all cases of HIV TB co infection 
 
HIV-TB: Anti TB Treatment 
First line drugs used in management of tuberculosis are : 
x isoniazid(H) ,  
x Rifampicin (R) ,  
x Pyrazinamide (Z) , 
x Ethambutol (E) ,  
x Streptomycin(S)4. 
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Isoniazid 
 It is a bactericidal drug. It acts both intracellularly and 
extracellularly.It is a prodrug. It acts by inhibiting cell wall synthesis. 
Resistance to isoniazid32 occurs due to 
x Overexpression of inhA 
x Mutation/Deletion of KatG gene 
x Promoter mutations 
x Kas A mutation 
Mutations causing resistance to isoniazid occurs in about 1 in 106 
replications19. 
Main adverse effects are hepatotoxicity and peripheral 
neuropathy. Other adverse effects are transient memory loss, seizures, 
psychosis, tinnitus, abdominal discomfort, gynaecomastia. 
Daily dose is 5mg/kg. Thrice weekly dose is 10mg/kg. 
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Rifampicin 
 It is also a bactericidal drug.It acts both intracellularly and 
extracellularly. It acts on both slow dividing cells and actively dividing 
bacilli. It has sterilizing effect. It binds to beta subunit of DNA 
dependent RNA polymerase and inhibits DNA dependent RNA 
synthesis32. 
Resistance of rifampicin 
- Mainly due to mutation in rpoB gene32. Mutations causing 
resistance to isoniazid occurs in about 1 in 108 replications19. 
It shows cross resistance to rifabutin and rifapentine. 
Major adverse effects are hepatotoxicity, respiratory syndrome, 
purpura, hemolysis, shock and renal failure. Minor reactions are, flu 
syndrome,cutaneous syndrome and abdominal syndrome, proteinuria, 
orange red urine, acute tubular necrosis22. 
Rifampicin  resistance  is  strong  correlator  of  MDR  TB.  Under  
RNTCP, those cases with rifampicin resistance are treated with 
Category IV ATT drugs4. 
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Regimen for HIV TB co-infected cases18 
Category of 
treatment18 
Type of Patient  Regimen 
New (Category I)  
1. New sputum smear positive 
2. New sputum smear negative 
3. New extra pulmonary TB 
2H3R3Z3E3 
     + 
4H3R3 
Previously treated 
(Category II)  
1. Sputum smear positive 
Relapse 
2. Sputum smear positive 
Failure 
3. Sputum smear positive 
Treatment after Default 
4. Others 
2H3R3Z3E3S3    
+ 
1H3R3Z3E3 
+ 
5H3R3E3 
 
Outcome of Anti-TB Treatment 
Outcome of TB Treatment in HIV patients without ART  depends 
on CD4 Count during initiation of ATT. Immune status (CD4%) 
decelerates even when patient is on Anti TB treatment (without ART)5. 
It is associated with increased death rate because of HIV and other 
opportunistic infection. ATT without ART in HIV patients is associated 
with increase in relapses and re infections because of persistence of TB 
bacilli and low immune response. 
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CD4% count falls while under Anti TB treatment without ART. 
Assessment CD4 % CD4 
count 
(cells/mm3) 
Viral load 
(copies/ml) 
0 month 
13.8 + 9 
182   + 
144 
13x105  + 
2.5x103 
End of  
Treatment 11 + 9 186 + 87 
3.8x105   +       
5.6x103 
p value < 0.001 NS 0.05 
 
This table is from the pilot study by Swaminathan.S et al, which 
evaluated the efficacy of RNTCP Anti-TB treatment in HIV patients, in 
the year 2000, when National ART Programme has not come into force.  
The study assessed the efficacy of RNTCP Anti-TB treatment in 
relation to the rise in  Immune status (CD4 count and CD4%) and fall in 
the viral burden.It  brings out an important quality assessment factor, 
demonstrating the considerable CD% decline, despite  6-months of 
supervised anti TB treatment, of course without ART. This explicitly 
underlines the significance of initiating ART also in those PLHIV 
patients with low CD4 counts. 
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Early  ART   Deferred ART 
 
Increase in cure rate, reduction in 
relapses 
Drug interaction decreased 
Early mortality due to TB is 
decreased. 
Reduction in toxicity 
Prevents other OI’s concurrently Decrease in IRIS  
Period of Hospitalization 
minimized 
ATT period can be used as a 
foundation for better adherence to 
ART 
Drug resistance caused by 
malabsorption can be reduced 
Management of ATT toxicity is 
crucial for subsequent ART 
adherence 
 
  
 This table compares the benefits of early versus deferred ART in 
HIV TB co-infected patients. While the dangers of IRIS and drug 
toxicities are present, the significant advantage of early ART is the 
considerable reduction in deaths. 
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Role of ART in Reducing Mortality5 
 
The graph on the left shows the overall survival rate of 730 HIV- 
TB co-infected patients which was 82% during TB treatment. 
The graph on the right side shows the cumulative survival rate of 
730  HIV  TB  co-infected  cases  with  or  without  ART  while  on  TB  
treatment. Among these cases, 363 HIV-infected TB patients were given 
ART also, had the survival rate of >88%. But, the survival rate of those 
367 HIV-infected TB patients, who did not receive ART was found to 
be<75%. This undoubtedly establishes the need of ART with ATT in the 
treatment of HIV infected TB patients to decrease the mortality rate. 
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Drug Interactions between ART and ATT 
 
 Rifampicin activates cytochrome P450 enzymes in the liver that 
metabolizes NNRTIs and PIs5. 
 Rifampicin notably reduces the bioavailability of Nevirapine and C 
min to sub-therapeutic levels in 62% of patients5. 
 Protease inhibitors and NNRTIs can enhance or inhibit this system 
leading to altered blood levels of many other drugs5. 
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First Line Antiretroviral therapy for HIV-TB co-infection in India5 
 The following Antiretroviral therapy regimens are used in the 
management of HIV TB co infected patients in India. 
 
 
 
 
 
The regimens used depend on the hemoglobin level of the patient. 
 
Regimen II 
Zidovudine + 
Lamivudine + 
Efavirenz 
Preferred regimen, if  
patient’s Hb >9gm/dl 
Regimen II 
(a) 
Tenofovir + 
Lamivudine + 
Efavirenz 
Preferred regimen if 
patient’s Hb <9 gm/dl  
 
 
 
 
      ZIDOVUDINE 
  OR             +   LAMIVUDINE    +   EFAVIRENZ5 
     TENOFOVIR 
30 
 
Initiation of ART in PLHIV with TB Co-infection 
Type of Tuberculosis  
 Pulmonary TB (Stage III) 
Extra pulmonary TB (Stage IV) 
Eligible Clinical Staging 
 Initiate ART irrespective of clinical stage  
Eligible CD4 Counts 
 Initiate ART irrespective of CD4 count 
Timing of ART in accordance with start of TB treatment 
x Start ATT first (Category I or II)  
x Start ART as soon as   TB treatment is tolerated5 
x after 2 weeks &  before 2 months 
ART Regimen 
 Start Efavirenz containing ART Regimen 
Patient should be monitored for toxicities associated with both ATT and 
ART. 
 
ART after Anti TB Treatment 
 Nevirapine containing regimen is used after completion of ATT5. 
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 For a period of one week Nevirapine and Efavirenz are given 
together. Then Efavirenz is discontinued. 
 Nevirapine is given in the dose of 200 mg bid 
 The major adverse effect associated with introduction of 
Nevirapine is Steven Johnson syndrome, which may at times be 
lethal. 
Immune Reconstitution Inflammatory Syndrome (IRIS): 
Tuberculosis 
 Antiretroviral therapy suppresses the viral replication and thus boosts 
the immunity of the patient. When immunity is restored  there is a 
rise in CD4 count . Since manifestations of TB is due to immune 
response, the boosted immunity mounts immune response against TB 
bacilli in the body leading to various manifestations like CNS TB , 
lymphadenopathy or worsening of lesions in lungs. This 
phenomenon is known as IRIS19. 
 There are two types of IRIS – unmasking or paradoxical reaction. 
Unmasking is occurrence of new lesions. Paradoxical reaction is 
worsening of existing symptoms. TB is the most common infection, 
manifesting as “IRIS”. 
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 Onset of symptoms is between 2 weeks and 2 months. It may occur 
even after one year in rare cases. Duration of symptoms is usually 3 
weeks. 
 
Second Line ART regimen for HIV-TB in India 
Tenofovir  +Lamivudine+Atazanavir/ritonavir 5 
 Second line regimen consists of two protease inhibitors in 
addition to first line drugs. Protease inhibitors are metabolized by 
Rifampicin and their blood levels are reduced. This leads to 
treatment failure. 
 Rifampicin is avoided in these patients. Rifabutin is used instead 
of Rifampicin. Rifabutin has less enzyme inducing property, so 
interaction with protease inhibitors is also less. 
 Dose of Rifabutin is 150mg, thrice a week. 
Causes for Drug Resistant TB in HIV18 
 It is mainly due to delay in diagnosis of Tuberculosis due to 
atypical presentation in HIV patients. 
 Another reason is the impaired absorption of Isoniazid & 
Rifampicin from the gut. Acquired MDR-TB is common in these 
patients. 
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 Primary Drug Resistance is also common in HIV TB co-infected 
patients. 
 Persistence of TB bacilli after treatment is high in these patients. 
So Relapse is common in these patients. 
 Nosocomial Drug Resistant TB is also possible in hospitalised 
HIV  patientsas their immunity is low. 
Drug Resistant TB in HIV Patients 
 MDR-TB among HIV patients in India 20121: 
 Primary MDR-TB: 2.2% 
 Acquired MDR-TB: 11-19% 
 MDR-TB suspects are subjected to line probe assayunder criteria C. 
According to criteria C , all HIV TB patients are MDR TB suspects. 
 Management Plan:  
 MDR TB: Category IV 
 XDR TB: Category V 
Pill burden in these patients is very high. In addition to the disease, 
toxicity of the drugs causes increased morbidity in these patients. 
MDR-TB: Definition & Treatment 
• A TB patient whose sputum is culture positive for Mycobacterium 
tuberculosis and is resistant in-vitro to  Isoniazid and Rifampicin 
34 
with or without other anti-tubercular drugs based on DST results 
from an RNTCP-certified Culture & DST Laboratory4 
•  Intensive Phase is for 6-9 months. 6 drugs used in this phase are 
Kanamycin, Pyrazinamide, Ethambutol ,Levofloxacin, Ethionamide 
and Cycloserine   
x The Continuation Phase is for 18 month. The 4 drugs used in this 
phase are Levofloxacin, Ethambutol, Ethionamide and  Cycloserine  
XDR-TB: Definition & Treatment 
• An MDR TB case whose recovered M. tuberculosis isolate is 
resistant to at least Isoniazid, Rifampicin,   a  fluoroquinolone 
(Ofloxacin, Levofloxacin, or Moxifloxacin) and a second-line 
injectable anti-TB drug (Kanamycin, Amikacin, or Capreomycin) at 
a RNTCP-certified Culture & DST Laboratory4 
• The duration of Intensive Phase is 6-12 months. The  7 drugs used in 
this phase are Capreomycin, PAS, Clofazimine, Moxifloxacin, High 
dose-INH,  Linezolid, and Amoxyclav  
• The duration of Continuation Phase is 18 months. The  drugs used in 
this phase are PAS, Moxifloxacin, Linezolid, High dose-INH,  
Clofazimine, and Amoxyclav  
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Isoniazid Prophylaxis Therapy (IPT)18 
 It consists of using isoniazid alone to reduce the incidence of TB 
in HIV patients. It can be given as daily regimen of 300mg for 6 months. 
Various studies have been done to assess the efficacy of IPT. The 
efficacy was just around 36% in most studies. The major challenge in 
implementing IPT is ruling out active TB infection. 
Unless active TB is ruled out, IPT may lead to isoniazid 
monoresistance. Further studies are needed before implementing IPT in 
national programme. Rifampicin can also be used for TB prophylaxis. 
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AIM: 
To determine the correlation between clinical, radiological, 
microbiological features and the drug resistance pattern of 
Mycobacterium tuberculosis in patients with HIV tuberculosis co 
infection. 
OBJECTIVES: 
1. To determine the relationship between clinical presentation of 
HIV -pulmonary tuberculosis co infection and drug 
resistance pattern. 
2. Correlate CD4 count and drug resistance pattern. 
3. Compare HIV staging and drug resistance pattern. 
4. Compare roentgenographic features of HIV TB co-
infection patients with sputum DST pattern. 
5. Compare sputum for AFB smear status with drug resistance 
pattern. 
6. Compare LPA and Gold standard Sputum culture and 
sensitivity.   
7.  Prevalence of MDR TB in HIV tuberculosis co infection. 
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MATERIALS AND METHODS 
Study design :   Prospective  
Study period :   April 2013 to March 2014 
Study population :   Patients admitted in GHTM 
Inclusion Criteria: 
1) All HIV seropositive patients with pulmonary TB. 
2) Age > 18 years 
Exclusion Criteria: 
1) HIV patients with only extrapulmonary TB 
2) Age < 18 years 
3) Patients who are moribund, sick and unable to produce sputum. 
4) Patients who are not willing to participate in the study    
5)Patients whose sputum showed no growth in LJ culture medium. 
METHODS: 
 Collection of clinical samples/ data:  
  1. Symptoms duration. 
  2. HIV diagnosis and treatment history 
  3. Antituberculous treatment history. 
  4. Height & Weight.  
  5. Chest radiograph. 
  6. Sputum for AFB staining, LPA, sputum Mtb culture 
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  7. CD4 count 
  8. Allotting score for each of the variable. Predict MDR 
based on score. Comparing prediction with sensitivity results and 
analyse. 
Features/score 0 1 2 
Contact H/o PT absent   present 
H/O ATT No   Yes 
HIV STAGE 4 No Yes   
CD4 count >200 <200   
BMI >18 <18   
Pulmonary TB alone with dissemination   
chest xray no cavity cavitation   
sputum smear negative positive   
 
 Drug susceptibility of all the samples were detected using line 
probe assay. For those cases which were reported as smear negative by 
line probe assay, were subjected to Lowenstein Jenson culture. 
M.Tuberculosis colonies grown in this culture medium were then 
subjected to line probe assay and drug sensitivity pattern was obtained. 
All sputum samples were grown in LJ medium and those cases whose 
culture was positive for M.Tuberculosis alone were included in this 
study. 
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Sensitivity pattern obtained by line probe assay were : 
LINE PROBE ASSAY REPORT DIAGNOSIS 
Sensitive to isoniazid(H) and 
rifampicin(R) 
Drug susceptible TB 
Sensitive to R , Resistant to H Monoresistant to H 
Sensitive to H , Resistant to R Monoresistant to R 
Resistant to H & R MDR 
 
In this study, Rifampicin monoresistance and MDR are 
considered together as Rifampicin resistance.  
Drug resistance includes isoniazid monoresistance, Rifampicin 
monoresistance and MDR.  
Source of the study population:  
Government Hospital of Thoracic Medicine, Tambaram 
Sanatorium, Chennai. 
Statistical analysis:  
Analysis is done using Epi info software.  
Ethical Clearance  
The various investigations and procedures that will be used in this 
study will be as per protocol. The identity of each patient will be kept 
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confidential. This study will not violate medical ethics in anyway and it 
will help to know the correlation between clinical, radiological, 
microbiological features and the drug resistance pattern of 
Mycobacterium tuberculosis in sputum in patients with HIV 
tuberculosis co infection 
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OBSERVATION AND RESULTS 
In the study of correlation of clinical, radiological, 
microbiological features and drug resistance pattern of mycobacterium 
tuberculosis in patients with HIV tuberculosis co-infectionthe following 
observations were made. 
In the period April 2013 to March 2014, totally 230 patients were 
diagnosed to be coinfected with Human Immunodeficiency Virus and 
Tuberculosis. 
Of these 230 patients, 198 were male, 32 were female. (Table 1) 
 
Sex Frequency Percent Cum.Percent 
Male 198 86.09% 86.09% 
Female 32 13.91% 100.00% 
Total 230 100.00% 100.00% 
Table 1 
 
 
Table 2 
  Obs Mean Std 
Dev 
Range 
AGE 230 39.54 8.49 18-65 
    
Mean age of the patients is 39.5(Table 2)
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Sex distribution 
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Prevalence of MDR TB 
          Rifampicin monoresistance and MDR are considered together as 
Rifampicin resistance. Drug resistance includes isoniazid 
monoresistance, Rifampicin monoresistance and MDR. 
 Total number of HIV TB co-infected cases is 230. 12 cases were 
found to be MDR TB,14 cases were monoresistant to isoniazid and 11 
cases were monoresistant to rifampicin(Table 3) 
Table 3 
Sensitivity pattern Frequency Percent 95% CI Lower 
95% CI 
Upper 
 
Sensitive to H,R 
193 83.9% 78.51% 88.41% 
 
Monoresistant To H 
14 6.1% 3.37% 10.00% 
 
Monoresistant To R 
11 4.8% 2.41% 8.40% 
 
MDR 
12 5.2% 2.72% 8.94% 
 Total 230 100% 
 
      
       Prevalence of MDR TB in HIV TB co infected patients is 5.2 %. 
Prevalence of Rifampicin Resistant TB cases is 10%. 
Table 4 
TB CASE Frequency Percent 95% CI Lower 
95% CI 
Upper 
New 148 64% 57.79% 70.53% 
Retreatment 82 36% 29.47% 42.21% 
TOTAL 230 100.00% 
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Out of 230 cases, 148(64%) were new TB cases and 82(36%) 
were retreatment cases (Table 4).Their drug sensitivity pattern is as 
follows : 
Prevalence of MDR in new cases is 3.4%. It rises to 8.5 % in 
retreatment cases.(Table 5& 6) 
            Prevalence of Rifampicin resistanceis 6.1%in new cases and 
19% in retreatment cases.(Table 5& 6) 
NEW TB CASE 
Table 5 
Sensitivity Pattern Frequency % 
95%CI 
Lower 
95% CI 
Upper 
Sensitive to H ,R 
132 89.2% 83.04% 93.69% 
Monoresistant to H 
7 4.7% 1.92% 9.50% 
Monoresistant to R 
4 2.7% 0.74% 6.78% 
MDR 
5 3.4% 1.11% 7.71% 
Total 148 100% 
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RETREATMENT TB CASE 
Table 6 
Sensitivity Pattern Frequency % 
95% CI 
Lower 
95% CI 
Upper 
Sensitive to H ,R 61 
74.4
% 
63.56% 83.40% 
Monoresistant to H 7 8.5% 
3.50% 16.80% 
Monoresistant to R 7 8.5% 
3.50% 16.80% 
MDR 7 8.5% 
3.50% 16.80% 
TOTAL 82 100% 
  
   
 In newly detected TB cases , 89.2% are dug susceptible TB, 4.7% 
are isoniazid monoresistant , 2.7% are rifampicin monoresistant and 
3.4% are MDR cases.(Table 5) 
 In retreatment TB cases , 74.4% are dug susceptible TB, 8.5% are 
isoniazid monoresistant , 8.5% are rifampicin monoresistant and 8.5% 
are MDR cases.(Table 6) 
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DRUG RESISTANCE PATTERN 
 
    TUBERCULOSIS CASE 
 
 
50 
New cases and drug resistance pattern 
Retreatment Cases & drug resistance pattern 
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Correlation between clinical presentation and drug resistance pattern 
  Clinical variables like TB Case (new or retreatment), HIV 
treatment(ART / not on ART),disseminated TB and duration of 
symptoms are compared with drug resistance pattern. 
TB case and drug resistance pattern 
  Drug resistance which includes resistance to single or both 
drugs is compared with tuberculosis case whether new or retreatment 
case.Odds ratio is 2.84 (1.39-5.82). p value is 0.003(p<0.05). p value is 
significant. (Table 7) 
Table 7 
 
 Sensitivity pattern  
TB Case Resistant to 
H/R/H&R 
Sensitive to H& 
R 
Total 
Retreatment 
21 61 82 
New 
16 132 148 
Total 
37 193 230 
Odds Ratio  
2.84 95% CI(1.39 - 5.82) 
Chi-square –p value 
0.003 
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Rifampicin resistance is compared with TB case. Odds ratio is 3.18 
(95%Cl 1.31-7.71). p value is 0.008(<0.05). p value is significant. 
(Table 8) 
Table 8 
Odds Ratio 3.18(95%CI 1.31- 7.71) 
Chi-square –p value 0.008 
TB CASE Sensitive  
to R 
Resistant  to 
R 
Total 
NEW 139 9 148 
RETREATMENT 68 14 82 
Total 207 23 230 
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Drug resistance and TB case 
 
 
 
 
Rifampicin resistance and TB case 
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HIV treatment and drug resistance pattern 
 Drug resistance of patients who were on ART was compared with 
those who were not on ART. 94 patients were on ART and 136 were not 
on ART. (Table 9) 
Table 9 
 
patients on ART not on ART 
Sensitivity Frequency Percent Frequency Percent 
sensitive to 
R 82 87% 125 92% 
Resistant  to 
R 12 13% 11 8% 
TOTAL 94 100.00% 136 100.00% 
 
     Table 10 
 
ON ART 
TB CASE = NEW 
Sensitivity  Frequency % 
sensitive to R 30 100% 
resistant to R 0 0% 
TOTAL 30 100% 
TB CASE = RETREATMENT 
Sensitivity Frequency % 
sensitive to R 52 81% 
resistant to R 12 19% 
TOTAL 64 100.% 
 
Rifampicin  resistance  is  seen  in  13%  of  cases  who  are  on  ART  and  in  
8% of ART naïve cases. (Table 9) 
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Table 11  
 
NOT ON ART 
TB CASE = NEW 
Sensitivity Frequency % 
sensitive to R 109 92% 
resistant to R 9 8% 
TOTAL 118 100% 
TB CASE = RETREATMENT 
Sensitivity Frequency % 
sensitive to R 16 89% 
resistant to R 2 11% 
TOTAL 18 100% 
  
 In patient on ART group there is no case of Rifampicin resistance 
in newly detected TB cases while in other group, there is 8% of 
rifampicin resistance in newly detected TB cases.( Table 10 &11) 
 HIV treatment and Rifampicin resistance is compared. Odds ratio 
is 0.60 (95%CI 0.25 – 1.43). p value is 0.24 (>0.05). p value is not 
significant. (Table 12) 
Table 12 
Sensitivity pattern 
HIV treatment Sensitive to R 
Resistant to 
R(including 
MDR) 
Total 
on ART 82 12 94 
not on ART 125 11 136 
Total 207 23 230 
Odds Ratio 0.60(95% CI 0.25 -1.43) 
Chi-square - p value 0.24 
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Disseminated TB and drug resistance pattern 
 Drug resistance pattern in pulmonary TB with and without 
dissemination. 10% of disseminated TB cases are MDR TB. 20 % are 
Rifampicin resistant. (Table 13) 
    Table 13 
Pulmonary TB with dissemination 
Sensitivity pattern Frequency Percent 
Sensitive to H ,R 31 74% 
Monoresistant to H 3 7% 
Monoresistant to R 4 10% 
MDR 4 10% 
TOTAL 42 100% 
     
Table 14 
Pulmonary TB without dissemination 
Sensitivity pattern Frequency Percent 
Sensitive to H ,R 162 86% 
Monoresistant to H 11 6% 
Monoresistant to R 7 4% 
MDR 8 4% 
TOTAL 188 100% 
 
  
MDR TB constitutes just 4% in TB without dissemination. (Table 14) 
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Drug resistance pattern in disseminated TB 
 
 
 
Drug resistance pattern in TB without dissemination 
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The association between disseminated TB and drug resistance pattern is 
assessed. Odds ratio is 2.21 (95%Cl 1.0-4.9). p value is 0.048.(<0.05). p 
value is significant. (Table 15) 
    Table 15 
Sensitivity pattern 
Disseminated 
TB 
Sensitive 
to H,R 
Resistant to 
H/R/H&R Total 
No 162 26 188 
Yes 31 11 42 
Total 193 37 230 
 
The association between disseminated TB and rifampicin resistance 
pattern is assessed. Odds ratio is 2.71(95%CL 1.07-6.09). p value is 
0.03(<0.05).p value is significant. (Table 16) 
    Table 16 
Sensitivity pattern 
Disseminated 
TB 
Sensitive 
to R 
Resistant  to R 
(including 
MDR) 
Total 
No 173 15 188 
Yes 34 8 42 
Total 207 23 230 
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Comparison of duration of symptoms and drug resistance pattern 
  4% of cases had MDR TB when duration of symptoms was 
less than 3 months. (Table 17) 12.9% cases had MDR TB when duration 
of symptoms was more than 3 months. (Table 18) 
    Table 17 
Symptoms duration <3months 
Sensitivity pattern Frequency Percent 95% CI  
 
Sensitive to H, R 167 84% 78% -88% 
Monoresistant to 
H 
13 7% 3%– 11% 
Monoresistant to 
R 
11 5% 3% - 10% 
MDR 8 4%             2%– 8% 
TOTAL 199 100.00% 
    
    Table 18 
                                 symptoms duration >3months 
Sensitivity 
Pattern 
Frequency Percent 95% CI range 
 
Sensitive to H ,R 26 84% 66 %  - 94 % 
Monoresistant to 
H 
1 3% 0%  - 17% 
Monoresistant to 
R 
0 0% 0% -  11% 
MDR 4 13% 4% - 30% 
Total 31 100.00% 
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The association between duration of symptoms and drug resistance 
pattern is assessed. Odds ratio is1.0.P value is 0.99.p value is not 
significant. (Table 19) 
    Table 19 
  Sensitivity pattern   
duration of 
symptoms 
Sensitive 
to H, R 
Resistance 
to H,R or 
H&R 
Total 
 <3months 167 32 199 
>3months 26 5 31 
Total 193 37 230 
Odds Ratio  1.00 (95% CI 0.36 - 2.81) 
Chi-square–p value 0.99 
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The association between duration of symptoms and rifampicin resistance 
pattern is assessed. Odds ratio is 1.4. p value is 0.56 (>0.05) p value is  
not significant. (Table 20) 
    Table 20 
 
symptoms 
duration 
Sensitivity pattern 
Total 
sensitive to 
R 
Resistant  to 
R (including 
MDR) 
<3months 
180 19 199 
>3months 
27 4 31 
Total 
207 23 230 
  
  
Point 95% Confidence Interval 
Estimate Lower Upper 
Odds Ratio 1.40 0.44 4.44 
 P value 
Chi-square  0.56 
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Comparison of  CD4 count and drug resistance pattern 
  When  the  CD4  count  was  less  than  200,  MDR  TB  was  
present in 8% of cases. In patients whose CD4 count is more than 200, 
MDR TB was seen in 1% of cases. (Table 21 &22) 
    Table 21 
CD4 COUNT <200 
Sensitivity 
pattern Frequency Percent 
95% CI 
Lower 
95% CI 
Upper 
Sensitive to H 
,R 116 80% 73% 86% 
Monoresistant 
to H 11 8% 4% 13% 
Monoresistant 
to R 7 5% 2% 10% 
MDR 11 8% 4% 13% 
Total 145 100.00% 
     
Table 22 
CD4 COUNT >200 
Sensitivity 
pattern Frequency Percent 
95% CI 
Lower 
95% CI 
Upper 
Sensitive to H 
,R 77 91% 82% 96% 
Monoresistant 
to H 3 4% 1% 10% 
Monoresistant 
to R 4 5% 1% 12% 
MDR 1 1% 0% 6% 
Total 85 100.00% 
 
Drug susceptible TB is present in 80% of cases when CD4 count is less 
than 200. It rises to 91% cases when the CD4 count is more than 200. 
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CD4 count less than 200 and drug resistance pattern 
 
 
CD4 count more than 200 and drug resistance pattern 
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CD4 count is compared with drug resistance pattern. Odds ratio is 
2.41(95%Cl 1.05 -5.54). p value is 0.035 (<0.05). p value is significant. 
(Table 23) 
    Table 23 
  Sensitivity pattern   
CD4 COUNT Resistance to H,R or H&R 
Sensitive to 
H, R Total 
<200 29 116 145 
>200 8 77 85 
Total 37 193 230 
 Point 95% Confidence Interval 
 Estimate Lower Upper 
Odds Ratio  
2.41 1.05 5.54 
Chi-square – p value 
0.035 
 
Table 24 
  Sensitivity pattern   
CD4 COUNT MDR Sensitive to H,R Total 
<200 11 116 127 
>200 1 77 78 
Total 12 193 205 
  Estimate Lower Upper 
Odds Ratio  7.30 0.92 57.71 
Chi-square - p value 0.029 
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CD4 count is compared in patients with MDR TB and sensitive cases. 
Odds ratio is 7.30(95%Cl 0.92-57.71). p value is 0.029(<0.05). p value 
is significant. (Table 24) 
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Comparison of  HIV staging and drug resistance pattern 
   Rifampicin resistance is  seen in 17% of HIV stage 4 
cases. It is seen in 7% of HIV stage 3 cases. (Table 25, 26) 
    Table 25 
HIV STAGE 4 
Sensitivity 
pattern Frequency Percent 95% CI  
sensitive to R 54 83% 72%-91% 
Resistant  to R 
(including 
MDR) 11 17% 9%-28% 
TOTAL 65 100% 
 
    Table 26 
HIV STAGE 3 
Sensitivity pattern Frequency Percent 95% CI   
sensitive to R 153 93% 88%-96% 
 Resistant  to R  
(including MDR) 12 7% 4%-12% 
TOTAL 165 100% 
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 HIV stage is compared with drug resistance pattern. Odds ratio is 
1.95. p value is 0.07(>0.05)p value is not significant. (Table 27) 
    Table 27 
Sensitivity pattern 
HIV STAGE 
Resistance 
to H,R or 
H&R 
Sensitive 
to H, R Total 
Stage 4 15 50 65 
Stage 3 22 143 165 
Total 37 193 230 
  Estimate Lower Upper 
Odds Ratio  1.95 0.94 4.05 
Chi-square - p value 0.070 
 
    Table 28 
  Sensitivity pattern   
HIV Stage 
Resistant  
to R 
(including 
MDR) 
Sensitive 
to R Total 
Stage 4 11 54 65 
Stage 3 12 153 165 
Total 23 207 230 
 Estimate Lower Upper 
Odds Ratio 2.59 1.08 6.23 
Chi-square - p value 0.028 
 
 
 HIV stage is compared with rifampicin resistance. Odds ratio is 
2.59. p value 0.028(<0.05).p value is significant. (Table 28) 
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Roentgenographic features and drug resistance pattern 
 Lung fields in chest x-ray are usually divided into 3 zones. Upper 
zone extends from apex to second costal cartilage. Mid zone extends 
from second to fourth costal cartilage. Lower zone extends from 4th 
costal cartilage to diaphragm. Thus lung fields are divided into 6 zones, 
3 on each side.. Number of zones in chest x-ray is compared with drug 
resistance pattern. Odds ratio is 2.30. p value is 0.094 (>0.05). p value is 
not significant.  (Table 29) 
     Table 29 
Sensitivity pattern 
ZONES Sensitive to H, R 
Resistance to 
H,R or H&R Total 
>3 51 5 56 
<3 142 32 174 
Total 193 37 230 
  Estimate Lower Upper 
Odds Ratio  2.30 0.85 6.22 
Chi-square - p value 0.094 
    Table 30 
Sensitivity pattern 
Zones Sensitive to R 
Resistant  
to R 
(including 
MDR) 
Total 
>3 52 4 56 
<3 155 19 174 
Total 207 23 230 
Odds Ratio 1.60 (95% CI 0.52-4.90) 
Chi-square - p value 0.41 
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Number of zones in chest xray is compared with drug resistance pattern. 
Odds ratio is 1.60. p value is 0.41.p value is  not significant. (Table 30) 
Cavitation is compared with drug resistance pattern. (Table 31) 
  Table 31 
  cavity present 
without cavity 
  
Sensitivity 
pattern Frequency % Frequency % 
Sensitive to H 
,R 21 81% 172 84% 
Monoresistant 
to H 1 4% 13 6% 
Monoresistant 
to R 3 12% 8 4% 
MDR 1 4% 11 5% 
TOTAL 26 100% 204 
100
% 
 
When presence of cavity is compared with drug resistance pattern the 
odds ratio is 0.78. p value is 0.22.p value is not significant. (Table 32) 
     Table 32 
Sensitivity pattern 
CAVITATION Sensitive to H, R 
Resistance 
to H,R or 
H&R 
Total 
Yes 21 5 26 
No 172 32 204 
Total 193 37 230 
Odds Ratio 0.78 (95%CI 0.28-2.22) 
Chi-square - p 
value 0.22 
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Comparison of sputum smear for AFB and drug resistance pattern 
  Out of 230 cases , 148 (64%)cases were sputum positive for AFB 
and 82 (36%)cases were smear negative for AFB. (Table 33) 
    Table 33 
Sputum 
smear Frequency Percent 
Negative 82 35.65% 
Positive 148 64.35% 
Total 230 100.00% 
 
     Table 34 
Sputum 
smear Frequency Percent 
Negative 82 36% 
Scanty 5 2% 
1+ 73 32% 
2+ 33 14% 
3+ 37 16% 
TOTAL 230 100.00% 
 
  Out of the 64% sputum smear positive cases, 16 % had 
smear grading 3+, 14% with grading of 2+ , 32% with grading 1+ and 
2% had scanty bacilli.  (Table 34) 
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Sputum smear status 
 
 
 
Sputum smear frequency 
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Drug resistance pattern in sputum smear positive and sputum smear 
negative cases is shown below. (Table 35, 36) 
   Table 35 
Sputum smear negative cases 
Sensitivity pattern Frequency Percent 
Sensitive to H ,R 66 80% 
Monoresistant to H 7 9% 
Monoresistant to R 6 7% 
MDR 3 4% 
Total 82 100.00% 
 
   Table 36 
Sputum smear positive cases 
Sensitivity pattern Frequency Percent 
Sensitive to H ,R 127 86% 
Monoresistant to H 7 5% 
Monoresistant to R 5 3% 
MDR 9 6% 
TOTAL 148 100.00% 
 
 Prevalence of MDR in sputum smear negative cases is 4% and in 
sputum smear positive cases, it is 6%. (Table 35, 36)
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 Sputum smear for acid fast bacilli is compared with drug 
resistance pattern. Odds ratio is 1.47. p value is 0.29(>0.05).p value is  
not significant. (Table 37) 
    Table 37 
Sensitivity 
Sputum smear Sensitive to H, R 
Resistance 
to H,R 
&H&R 
Total 
Positive 127 21 148 
Negative 66 16 82 
Total 193 37 230 
  Estimate Lower Upper 
Odds Ratio  1.47 0.72 3.0 
Chi-square - p 
value 0.29 
 
Sputum  smear  for  acid  fast  bacilli  is  compared  with  rifampicin  
resistance (including MDR TB cases). (Table 38) 
    Table 38 
Sensitivity pattern 
Sputum smear Sensitive to R 
Resistant  
to R 
(including 
MDR) 
Total 
Positive 134 14 148 
Negative 73 9 82 
Total 207 23 230 
 
 Odds ratio is 1.18 (95% CI 0.49 – 2.86). p value is 0.71 (>0.05).p 
value is  not significant. (Table 38) 
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Comparison of Line probe assay and Lowenstein Jenson culture 
  Line probe assay results which showed smear negative was 
compared with culture and drug sensitivity. Out of 230 cases, drug 
sensitivity pattern was obtained directly using line probe assay in 154 
cases. (Table 39)76 cases were smear negative by line probe assay. 
(Table 40)  
   Table 39 
Line probe assay 
Sensitivity pattern Frequency Percent 
Sensitive to H ,R 130 84% 
Monoresistant to H 9 6% 
Monoresistant to R 7 5% 
MDR 8 5% 
Total 154 100.00% 
 
Those 76 cases were subjected to culture and drug sensitivity pattern 
obtained by subjecting culture isolates to line probe assay. (Table 40) 
   Table 40  
Culture LJ medium 
Sensitivity pattern Frequency Percent 
Sensitive to H ,R 63 83% 
Monoresistant to H 5 7% 
Monoresistant to R 4 5% 
MDR 4 5% 
TOTAL 76 100.00% 
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Table 41 
Sensitivity pattern = Sensitive to H ,R 
LPA Frequency Percent 
Smear negative 63 33% 
Sensitive To H & R 130 67% 
TOTAL 193 100.00% 
    
Table 42 
Sensitivity pattern = Monoresistant to H 
LPA Frequency Percent 
Smear negative 5 36% 
Monoresistantto H  9 64% 
TOTAL 14 100.00% 
   
   Table 43 
Sensitivity pattern = Monoresistant to R 
LPA Frequency Percent 
Smear negative 4 36% 
Resistant To R Alone 7 64% 
TOTAL 11 100.00% 
    
Table 44 
Sensitivity pattern = MDR 
LPA Frequency Percent 
Smear negative 4 33% 
MDR 8 67% 
TOTAL 12 100.00% 
 
 
 This table shows that 67% of MDR TB cases were detected using 
line probe assay and only 33% required Lowenstein Jenson culture to 
identify the drug sensitivity pattern.  (Table 44) 
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Scoring and drug resistance    
                                 Table 45 
Features/score 0 1 2 
Contact H/o PT absent   present 
H/O ATT No   Yes 
HIV STAGE 4 No Yes   
CD4 count >200 <200   
BMI >18 <18   
Pulmonary TB alone with dissemination   
chest xray no cavity cavitation   
sputum smear negative positive   
 
  Scoring was done using these variables (Table 45). 
Maximum score possible was 10. Patients were divided into two groups 
with a cutoff point of 4. (Table 46, 47) 
Table 46 
Score less than 4 
Sensitivity pattern Frequency Percent 
Sensitive to H ,R 147 86% 
Monoresistant to H 11 6% 
Monoresistant to R 5 3% 
MDR 7 4% 
Total 170 100.00% 
    
Table 47 
Score more than 4 
Sensitivity pattern Frequency Percent 
Sensitive to H,R 46 77% 
Monoresistant to H 3 5% 
Monoresistant to R 6 10% 
MDR 5 8% 
Total 60 100.00% 
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Score less than 4 and drug resistance pattern 
 
 
Score more than 4 and drug resistance pattern      
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This shows that drug susceptible cases are 86% when score is less 
than 4. It falls to 77% when score is more than 4. (Table 46, 47) 
Scoring and drug resistance pattern is compared. 
   Table 48 
Sensitivity pattern 
Score Sensitive to H, R 
Resistance 
to H,R 
orH&R 
Total 
Less than 4 147 23 170 
More than 4 46 14 60 
Total 193 37 230 
 
Odds ratio is 1.95 (95%Cl 0.93 - 4.09). Chi square gives p value of 
0.076(>0.05). p value is not significant. (Table 48) 
Scoring and Rifampicin resistance  
 Comparison of score and rifampicin resistance is shown in 
following table. (Table 49) 
   Table 49 
  Sensitivity pattern   
Score Sensitive to R 
Resistant  to R 
(including 
MDR) 
Total 
Less than 4 158 12 170 
More than 4 49 11 60 
Total 207 23 230 
 Odds ratio is 2.96 (95% Cl 1.23 – 7.12). p value is 0.01(<0.05).p 
value is significant. (Table 49) 
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DISCUSSION 
 In the following discussion, Rifampicin 
monoresistance and MDR are considered together as 
Rifampicin resistance. Drug resistance includes isoniazid 
monoresistance, Rifampicin monoresistance and MDR.  
Prevalence of MDR TB 
 In India, according to WHO report 2013, the estimated 
the prevalence of MDR-TB is about 2.2% in new cases and 
15% (11-19%)  in re-treatment cases1. 
 This study shows prevalence of MDR TB to be 3.4% 
in new cases and 8.5% in retreatment cases. Prevalence of 
Rifampicin resistance in new cases is 6.1% and that in 
retreatment cases is 19%. It was also found that prevalence of 
drug sensitive TB fell from 89% in new cases to 74% in 
retreatment cases. 
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Clinical presentation 
Clinical variables like type of TB case (New or retreatment), 
treatment for HIV, disseminated TB and duration of symptoms 
were compared with drug resistance pattern. 
Tuberculosis case  
 When type of TB case (new or retreatment) was 
compared with drug resistance pattern, it was found that drug 
resistance was 2.8 times more common in retreatment case. 
Odds ratio was 2.84 (95% CI 1.39–5.82). P value obtained by 
chi square was 0.003(<0.05). p value is significant. There is 
strong correlation between retreatment and drug resistance. It 
was shown that Rifampicin resistance was 3.2 times more 
likely in retreatment cases. There was significant association 
between retreatment case and Rifampicin resistance [p value 
0.008 (<0.05)] 
 It is similar to the results obtained from the study of 
Rajasekaran et al, which showed prevalence of drug resistance 
is more in chronic TB patients34. 
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HIV treatment 
 Drug resistance pattern of patients who were on ART was 
compared with those who are not on ART. 94 (41%)patients 
were on ART while 136(59%) were ART naïve. 
 Rifampicin resistance in patients taking ART was 13% 
compared to 8% in other group.It may appear controversial as 
patients on ART have more Rifampicin resistance. But on 
analyzing the prior history of treatment for tuberculosis, it 
shows that there was no case of Rifampicin resistance in newly 
detected TB cases, when the patient is on ART. Rifampicin 
resistance was present in 8% of newly detected TB cases when 
patient is not on ART. But Rifampicin resistance was more(12 
cases) in retreatment cases of TB in patients taking ART, 
compared to 2 cases in retreatment of tuberculosis in patients 
not on ART. 
 HIV treatment is not associated with Rifampicin 
resistance. This is shown by odds ratio of 0.60 and p value 0f 
0.24. p value is  not significant. 
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Disseminated TB  
 Drug resistance pattern in pulmonary TB with 
dissemination was compared with pulmonary TB without 
dissemination. Rifampicin resistance was 20 % in disseminated 
TB group compared to 8 % in pulmonary TB without 
dissemination. Drug susceptible TB constituted 74 % in 
disseminated TB group, compared to 86% in pulmonary TB 
without dissemination. Drug resistance was 2.2 times more 
likely in disseminated TB group [Odds ratio was 2.2(95% CI 
1.0 - 4.9)]. Rifampicin resistance was 2.7 times more likely in 
disseminated TB group [Odds ratio 2.7(95%CI 1.07- 6.09). 
Association between Rifampicin resistance and disseminated 
TB is statistically significant. P value is 0.03(<0.05). 
Duration of symptoms  
 Rifampicin resistance was 9% when symptoms’ duration 
was less than 3 months and 13% when duration was more than 
3 months. Drug susceptible TB was 84% in both groups. There 
was no significant association between Rifampicin resistance 
and duration of symptoms. P value is 0.56 (>0.05). p value is 
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not significant. Thus Rifampicin resistance must be suspected 
in all cases irrespective of duration of symptoms.  
CD4 count  
 When the CD4 count is less than 200, MDR TB was seen 
in  8%  of  cases.  But  with  higher  CD4  count,  MDR  TB  
constitutes just 1% of cases. Rifampicin resistance was 13% in 
group with low CD4 count compared to 6% in other group. 
Drug resistance was 2.4 times more likely when CD4 count is 
low.[Odds ratio 2.41(95% CI 1.05 – 5.54)]. MDR TB was 7.3 
times more likely when CD4 count is less than 200. [Odds ratio 
7.3 (95%CI 0.92 – 57.71)]. There is a strong association 
between MDR TB and low CD4 count. P value is 0.029 
(<0.05). p value is significant.  
HIV stage 
 Pulmonary TB indicates HIV stage 3. Extrapulmonary 
TB constitutes HIV stage 4. Rifampicin resistance was present 
in 17% of cases in stage 4 and in 7% cases in stage 3. There 
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was no significant association between drug resistance and 
stage of HIV disease. p value is 0.07(>0.05). But Rifampicin 
resistance was 2.6 times more likely in HIV stage 4 [Odds ratio 
2.6(95%CI 1.08 – 6.23)]. Rifampicin resistance was 
significantly associated with HIV stage 4. p value 
0.028(<0.05). p value is significant. 
Chest X-ray features 
 Presence or absence of 3 or more zones in a chest x-ray 
was compared with drug resistance pattern. There was no 
significant association between them. p value is 0.094(>0.05). 
p value is not significant. 
Cavitation 
 Out of total 230 cases, cavity was present only in 26 
cases. Out of 12 MDR cases, cavity was present only in one 
case. There was no significant association between cavitation 
and drug resistant TB. P value is 0.22(>0.05).p value is not 
significant. 
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Sputum smear for AFB  
 148 cases (64%) were sputum smear positive for AFB. 
Rest 82 cases (36%) were smear negative for AFB. Among 
these cases 2% had scanty bacilli, 32% had grade 1+, 14% had 
grade 2+, 16% had grade 3+.  
MDR TB among smear negative cases is 4% compared to 
6% in smear positive cases. Rifampicin resistance was 11% in 
smear  negative  cases  and  9  %  in  smear  positive  cases.  There 
was no significant association between sputum smear status 
and Rifampicin resistance. p value is 0.71(>0.05). p value is 
not significant. Thus drug resistance must be suspected 
irrespective of sputum smear status. 
Line probe assay 
 Sensitivity pattern was directly detected by line probe 
assay from sputum samples in 154(67%) cases. Sensitivity of 
LPA is 67% in this study group. Rest 76 cases (33%) were 
smear negative by line probe assay. These 76 samples were 
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inoculated in LJ culture and colonies grown were subjected to 
LPA. Rifampicin resistance was 10% in both groups.  
Among  12  MDR  TB  cases,  LPA  was  able  to  detect  8  
cases (67%) directly from sputum sample while 4 cases (33%) 
were detected after using LJ culture medium. Sensitivity of 
LPA is 67% in drug susceptible TB, 64 % in isoniazid 
monoresistant cases and 64 % in Rifampicin monoresistant 
cases. This is due to paucibacillary state of sputum in HIV 
positive patients. This decreased sensitivity of LPA in HIV 
patients, highlights the need for various rapid diagnostic 
methods in this high risk group of patients. 
MDR prediction score  
 This score was sum of variables like contact history of 
tuberculosis, prior TB treatment history, HIV stage, CD4 
count, BMI, disseminated TB, cavitation, sputum smear status. 
First 2 variables were given values of 0 or 2, other variables 
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were given value of 0 or 1. Scoring was out of 10 with 0 as 
minimum value. Cut off point was arbitrarily taken as 4. 
 Rifampicin resistance was present in 18 % of cases when 
score was more than 4 and in 7% cases when score was less 
than 4. Rifampicin resistance was 3 times more likely when 
score is more than 4[Odds ratio 2.96(95%CI 1.23-7.12)] . 
There is a significant association between Rifampicin 
resistance and score more than 4. P value is 0.01(<0.05). p 
value is significant.  
 In a study by Telzak et al, history of prior treatment 
for tuberculosis was the only predictor for MDR-TB in a group 
of HIV-infected patients with tuberculosis. 
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CONCLUSION 
  In summary, prevalence of MDR TB in this study is 
2.2% in new cases and 8.5% in retreatment cases. Prevalence 
of Rifampicin resistance in new cases is 6.1% and that in 
retreatment cases is 19%.  
History of prior treatment of tuberculosis, HIV stage 4, 
disseminated TB were significantly associated with rifampicin 
resistance. 
In this study, CD4 count less than 200 was significantly 
associated with MDR TB and drug resistant TB. 
HIV treatment was not associated with drug resistance 
pattern. Duration of symptoms did not affect prevalence of 
MDR TB. There was no significant association between chest x 
ray lesions, cavitation with MDR TB. Sputum smear status 
had no significant relation with MDR TB. 
Scoring with 8 variables with score more than 4 was 
significantly associated with Rifampicin resistance. Since the 
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study population is small, further studies with large study 
population will be helpful in validating this score. 
 Sensitivity of line probe assay in this study is 67%.Since 
scoring has significant association with Rifampicin resistant 
TB, it can help in predicting drug resistance in those cases for 
which are smear negative by LPA. These cases may be 
subjected to other diagnostic modalities like bronchoscopy , 
gene expert for early diagnosis of MDR TB. New techniques 
are required for rapid diagnosis in this paucibacillary state is 
required. This will help in reducing morbidity and mortality of 
HIV TB co-infected patients.  
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Annexures 
PROFORMA 
y Name              :  
y Age      :                    
y Gender    :    
y Height/Weight                        :  
y Body mass index   :  
y On ART / Not on ART  : 
y Contact history of Tuberculosis: Yes/No  
y Previous history of Tuberculosis treatment:  
y HIV stage 4     :Yes/No 
y Disseminated tuberculosis :Yes/No 
y Symptoms duration  : 
y Laboratory investigations        :  Chest   Xray,  Sputum Smear for  
AFB, HIV, CD4 count, ,LPA, DST  
y Cavities in chest x-ray  :Yes/No 
y Zones involved in xray  : 
y Score     :  
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Scoring done using following variables 
Features/score 0 1 2 
Contact H/o PT absent   present 
H/O ATT No   Yes 
HIV STAGE 4 No Yes   
CD4 count >200 <200   
BMI >18 <18   
Pulmonary TB alone with dissemination   
chest xray no cavity cavitation   
sputum smear negative positive   
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CONSENT FORM 
 
 I Mr / Mrs / Miss / ____________________________ have 
understood the procedure read by the Doctors. I in my whole conscious 
awareness give consent for the procedure. I understand that the 
procedure is done in good faith for the best therapeutic results possible. I 
fully understand the consequences of the procedure. I can resign from 
the study at any point of time. 
         
 
Signature  
Name    :  
Date and Time  : 
 
Signature of Researcher   : 
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2 928072013 34 MALE 1.65 15.43 No No No 122 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No No Yes No No Yes 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 60 1 3 not on ART
3 37102002 37 MALE 1.67 14.3425723 No No No 231 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes No Yes Yes No 0 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
1 30 0 4 not on ART
4 2139012014 65 MALE 1.55 18.73 No No No 134 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No Yes Yes No Yes Yes No 0 0 0 0 0 0 SENSITIVE TO H ,R NEW 0 365 1 1 not on ART
5 1625062013 40 MALE 1.55 17.8980229 No No No 509 2+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes No No Yes No No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 120 0 2 not on ART
6 5596022008 32 FEMAL
E
1.54 20.661157 No No No 413 3+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes No Yes Yes No 0 2 0 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
1 30 0 3 on ART
7 240062008 33 MALE 1.74 16.51 No No No 146 SCANTY 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R Yes Yes No No No No Yes 0 0 1 1 0 0 SENSITIVE TO H ,R NEW 1 30 1 4 not on ART
8 1565092013 24 MALE 1.56 16.4365549 No No No 374 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes Yes No No No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 60 0 2 not on ART
9 10052012 38 MALE 1.57 15.82 No No No 153 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes Yes Yes Yes Yes 0 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
1 30 1 5 on ART
10 2799062013 39 MALE 1.56 16.025641 No Yes No 241 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No No No Yes No No No 1 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
0 15 0 4 on ART
11 5179032002 37 MALE 1.69 16.1058786 No No No 218 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No No No Yes No No 0 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
1 30 0 4 on ART
12 114112013 48 MALE 1.56 20.96 No No No 59 2+ 2- RESISTANT TO H ALONE 2-RESISTANT TO H ALONE No Yes No No No Yes No 0 0 0 0 0 0 RESISTANT TO H NEW 1 15 1 2 not on ART
13 853062003 56 MALE 1.64 15.62 No No No 157 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No Yes No No Yes No No 0 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
0 30 1 4 on ART
14 330032013 33 MALE 1.65 13.96 No No No 7 2+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No No No No No Yes 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 90 1 3 on ART
15 2605122013 60 MALE 1.63 13.93 No No No 234 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No Yes Yes Yes No No No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 0 60 0 1 not on ART
16 1280112005 48 MALE 1.62 15.24 No No No 75 1+ 2- RESISTANT TO H ALONE 2-RESISTANT TO H ALONE Yes Yes No No No Yes No 0 2 1 1 0 0 RESISTANT TO H RETREATMEN
T
1 7 1 6 on ART
17 1774062004 39 MALE 1.64 13.01 Yes Yes Yes 13 1+ 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No Yes Yes No Yes Yes Yes 1 0 1 0 2 1 SENSITIVE TO H ,R NEW 1 30 1 7 not on ART
18 11122013 52 MALE 1.53 17.09 No No No 117 2+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes Yes Yes Yes Yes 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 30 1 3 not on ART
19 2449012012 54 FEMAL
E
1.58 14.02 No No No 87 3+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes No Yes Yes No 0 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
1 90 1 5 on ART
20 1328122013 37 FEMAL
E
1.6 15.63 No No No 208 NEGATIVE 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes No Yes Yes No No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 0 30 0 1 not on ART
21 2788022014 36 MALE 1.64 13.01 No No No 535 NEGATIVE 2- RESISTANT TO H ALONE 2-RESISTANT TO H ALONE No Yes Yes No Yes Yes No 0 2 1 0 0 0 RESISTANT TO H RETREATMEN
T
0 90 0 3 not on ART
22 1746122013 37 MALE 1.71 16.76 No No No 82 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes No No No No No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 7 1 3 not on ART
23 2935072006 33 MALE 1.69 17.86 No No No 766 SCANTY 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R Yes No Yes Yes No No Yes 0 2 1 1 0 0 SENSITIVE TO H ,R RETREATMEN
T
1 7 0 5 on ART
24 743072013 58 MALE 1.64 16.73 Yes No No 388 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No Yes Yes No No No No 0 0 1 0 2 0 SENSITIVE TO H ,R NEW 0 30 0 3 not on ART
25 1288052013 35 MALE 1.65 16.8962351 No No No 18 3+ 4 - MDR 4-MDR No No No No No Yes No 0 0 1 0 0 0 MDR NEW 1 90 1 3 not on ART
26 3390102013 28 MALE 1.63 13.55 No No No 84 1+ 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No Yes Yes No No No No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 180 1 3 on ART
27 4310052006 43 MALE 1.58 11.62 No No No 369 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No No Yes No No No 0 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
1 365 0 4 on ART
28 1854062013 28 MALE 1.6 16.8 No No No 169 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No No No No No Yes No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 0 90 1 2 not on ART
29 1948022014 45 MALE 1.64 16.36 No No No 78 1+ 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No Yes Yes No No No No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 7 1 3 not on ART
30 2852112013 40 MALE 1.5 15.56 No No No 25 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No No No Yes No No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 120 1 3 not on ART
31 375022014 40 MALE 1.59 18.2 No No No 489 3+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes Yes Yes Yes Yes 0 0 0 0 0 0 SENSITIVE TO H ,R NEW 1 540 0 1 on ART
32 2288032013 46 MALE 1.6 14.84 No Yes No 43 1+ 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No Yes No No No No No 1 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
1 14 1 6 on ART
33 571712004 53 MALE 1.59 14.239943 No No No 38 3+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R Yes No No No Yes Yes No 0 2 1 1 0 0 SENSITIVE TO H ,R RETREATMEN
T
1 15 1 6 on ART
34 313062013 37 MALE 1.62 20.58 No No No 13 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No No No No No No 0 0 0 0 0 0 SENSITIVE TO H ,R NEW 1 30 1 2 not on ART
35 1147112013 31 MALE 1.57 12.58 No No No 280 3+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R Yes Yes Yes Yes Yes Yes Yes 0 0 1 1 0 0 SENSITIVE TO H ,R NEW 1 120 0 3 not on ART
36 3146122013 49 MALE 1.65 13.96 No Yes Yes 144 NEGATIVE 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes No No No No No 1 0 1 0 0 1 SENSITIVE TO H ,R NEW 0 7 1 4 on ART
37 2737112013 53 FEMAL
E
1.5 13.33 No No No 187 3+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No No Yes No Yes Yes 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 90 1 3 not on ART
38 1953012007 36 MALE 1.7 15.57 No No No 110 3+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes No Yes Yes No 0 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
1 180 1 5 not on ART
39 2964082010 48 MALE 1.57 13.3879671 No No No 250 NEGATIVE 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes Yes Yes Yes Yes 0 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
0 30 0 3 not on ART
40 1764012014 37 MALE 1.62 14.86 Yes Yes No 184 1+ 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No Yes Yes Yes No No No 1 2 1 0 2 0 SENSITIVE TO H ,R RETREATMEN
T
1 30 1 8 not on ART
41 418042013 50 MALE 1.58 16.0230732 No Yes No 391 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No No No Yes No No No 1 0 1 0 0 0 SENSITIVE TO H ,R NEW 0 90 0 2 not on ART
42 5917072004 33 FEMAL
E
1.59 17.01 No Yes Yes 223 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes Yes Yes Yes Yes 1 2 1 0 0 1 SENSITIVE TO H ,R RETREATMEN
T
1 7 0 6 not on ART
43 405603213 27 MALE 1.7 17.3010381 No Yes Yes 120 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No No No No No Yes 1 0 1 0 0 1 SENSITIVE TO H ,R NEW 1 10 1 5 not on ART
44 2121052009 32 FEMAL
E
1.52 10.39 Yes No No 66 3+ 3- RESISTANT TO R ALONE 3-RESISTANT TO R ALONE No Yes Yes Yes Yes No No 0 2 1 0 2 0 RESISTANT TO R RETREATMEN
T
1 90 1 7 on ART
45 3468092013 50 MALE 1.66 15.97 No Yes No 40 2+ 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No Yes Yes Yes No No No 1 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 60 1 4 not on ART
46 158022014 46 MALE 1.61 13.5 No No No 341 2+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes No No No No No 0 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
1 90 0 4 on ART
47 2620022013 36 FEMAL
E
1.58 15.62 No Yes Yes 8 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No No No No No No 1 2 1 0 0 1 SENSITIVE TO H ,R RETREATMEN
T
1 90 1 7 on ART
48 3644022014 35 MALE 1.6 16.41 No Yes Yes 122 NEGATIVE 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No No No No No No 1 2 1 0 0 1 SENSITIVE TO H ,R RETREATMEN
T
0 2 1 6 on ART
49 816022014 29 MALE 1.77 12.77 No Yes No 56 3+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes No No Yes Yes Yes 1 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 30 1 4 not on ART
50 3004052004 32 MALE 1.72 19.61 No No No 150 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No Yes No No No No No 0 0 0 0 0 0 SENSITIVE TO H ,R NEW 0 7 1 1 not on ART
51 2039022014 44 MALE 1.6 13.67 No No No 247 NEGATIVE 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes Yes Yes Yes Yes 0 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
0 5 0 3 on ART
52 2335122013 49 MALE 1.69 14.0051119 No No No 425 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R Yes Yes Yes No Yes Yes No 0 2 1 1 0 0 SENSITIVE TO H ,R RETREATMEN
T
1 60 0 5 not on ART
53 6162082004 38 FEMAL
E
1.55 12.07 No Yes No 125 NEGATIVE 0 -SMEAR NEGATIVE 4-MDR No No No Yes No No No 1 2 1 0 0 0 MDR RETREATMEN
T
0 180 1 5 on ART
54 916122005 46 MALE 1.69 16.1058786 No Yes Yes 255 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No Yes No No No No 1 2 1 0 0 1 SENSITIVE TO H ,R RETREATMEN
T
1 7 0 6 on ART
55 1099062002 18 MALE 1.67 16.14 No No No 569 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No No No No Yes No No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 0 0 1 on ART
56 677082013 48 FEMAL
E
1.54 25.3 No No No 338 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No Yes No No No No No 0 2 0 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
0 0 2 on ART
57 5827062005 36 MALE 1.64 15.6157049 No Yes Yes 336 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No Yes No No Yes No No 1 2 1 0 0 1 SENSITIVE TO H ,R RETREATMEN
T
0 3 0 5 on ART
58 1903072013 31 MALE 1.62 18.67 Yes No No 146 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No No No No No No No 0 0 0 0 2 0 SENSITIVE TO H ,R NEW 0 60 1 3 not on ART
59 3102004 33 MALE 1.7 15.92 No No No 101 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No Yes Yes Yes Yes Yes Yes 0 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
0 1 4 on ART
60 2286082013 29 MALE 1.63 15.06 No Yes Yes 237 NEGATIVE 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes No No Yes No No 1 0 1 0 0 1 SENSITIVE TO H ,R NEW 0 42 0 3 not on ART
61 3713032013 36 MALE 1.69 15.0554953 No Yes Yes 42 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No No No No No No No 1 0 1 0 0 1 SENSITIVE TO H ,R NEW 0 7 1 4 not on ART
62 334032014 30 MALE 1.69 14.0051119 No Yes Yes 233 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes No No Yes No No 1 0 1 0 0 1 SENSITIVE TO H ,R NEW 1 90 0 4 on ART
63 3003052013 40 MALE 1.68 14.17 No No No 197 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R Yes Yes No No No No No 0 0 1 1 0 0 SENSITIVE TO H ,R NEW 1 90 1 4 on ART
64 820032002 53 MALE 1.65 16.16 No Yes Yes 119 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No No No No No No No 1 2 1 0 0 1 SENSITIVE TO H ,R RETREATMEN
T
0 10 1 6 on ART
65 4685112008 51 MALE 1.65 16.53 No Yes Yes 46 2+ 3- RESISTANT TO R ALONE 3-RESISTANT TO R ALONE No No No No Yes No No 1 2 1 0 0 1 RESISTANT TO R RETREATMEN
T
1 90 1 7 on ART
66 5070012008 39 MALE 1.62 18.29 No No No 189 2+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R Yes Yes No No Yes No No 0 2 0 1 0 0 SENSITIVE TO H ,R RETREATMEN
T
1 15 1 5 on ART
67 2395032012 36 MALE 1.63 15.4315179 No No No 295 3+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes No No Yes No No 0 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
1 60 0 4 not on ART
68 162112011 35 FEMAL
E
1.54 18.974532 Yes Yes Yes 371 NEGATIVE 0 -SMEAR NEGATIVE 3-RESISTANT TO R ALONE No No No Yes No Yes No 1 2 0 0 2 1 RESISTANT TO R RETREATMEN
T
0 30 0 6 on ART
69 4581012007 41 MALE 1.65 13.22 No No No 785 2+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes No No Yes No No 0 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
1 7 0 4 on ART
70 334102013 28 FEMAL
E
1.59 13.45 No Yes Yes 35 2+ 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No No Yes No Yes No Yes 1 0 1 0 0 1 SENSITIVE TO H ,R NEW 1 30 1 5 not on ART
71 3068022014 38 MALE 1.62 15.24 No No No 323 3+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes No No Yes Yes Yes 0 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
1 30 0 4 on ART
72 7131052007 45 MALE 1.59 17.7999288 No No No 28 2+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes Yes Yes Yes Yes 0 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
1 30 1 5 on ART
73 746022014 30 MALE 1.57 15.82 No No No 521 3+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes No Yes No Yes 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 30 0 2 not on ART
74 2142012012 32 MALE 1.6 12.890625 No No No 203 NEGATIVE 0 -SMEAR NEGATIVE 2-RESISTANT TO H ALONE No No No No Yes No No 0 0 1 0 0 0 RESISTANT TO H NEW 0 10 0 1 on ART
75 112112001 46 MALE 1.69 14.0051119 No Yes No 179 3+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No No Yes No No No 1 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
1 90 1 6 on ART
76 1782052008 37 MALE 1.62 16.38 No No No 227 NEGATIVE 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes No No No No No 0 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
0 7 0 3 on ART
77 2988122011 34 MALE 1.65 14.33 No Yes No 145 NEGATIVE 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R Yes Yes Yes Yes Yes Yes Yes 1 2 1 1 0 0 SENSITIVE TO H ,R RETREATMEN
T
0 60 1 6 on ART
78 2590012013 39 MALE 1.68 14.17 No No No 93 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No Yes No No No No No 0 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
0 30 1 4 on ART
79 2957012014 41 MALE 1.57 13.39 No No No 158 2+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No No No No No Yes 0 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
1 20 1 5 not on ART
80 3205012014 51 MALE 1.56 16.44 No No No 13 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes No No No No No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 60 1 3 not on ART
81 2737102013 47 MALE 1.65 17.63 No No No 454 2+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes No No No Yes No 0 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
1 30 0 4 not on ART
82 166092009 43 MALE 1.54 18.97 No No No 35 3+ 4 - MDR 4-MDR Yes Yes Yes Yes Yes Yes Yes 0 2 0 1 0 0 MDR RETREATMEN
T
1 180 1 5 on ART
83 2306112013 37 MALE 1.64 14.13 No No No 138 3+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R Yes Yes Yes No Yes Yes No 0 0 1 1 0 0 SENSITIVE TO H ,R NEW 1 30 1 4 not on ART
84 3936032013 32 FEMAL
E
1.53 14.95 No No No 149 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No Yes Yes No No No Yes 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 0 90 1 2 not on ART
85 2966102013 45 MALE 1.64 20.4491374 No No No 429 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No No No Yes Yes Yes 0 0 0 0 0 0 SENSITIVE TO H ,R NEW 1 20 0 1 not on ART
86 1850062013 20 MALE 1.62 11.4311843 No No No 162 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No Yes No No No No No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 0 60 1 2 not on ART
87 774112013 38 MALE 1.61 11.57 Yes Yes No 55 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes Yes Yes Yes Yes 1 0 1 0 2 0 SENSITIVE TO H ,R NEW 1 90 1 6 not on ART
88 2474062013 55 MALE 1.58 16.42 No No No 116 NEGATIVE 0 -SMEAR NEGATIVE 2-RESISTANT TO H ALONE No Yes No No Yes No No 0 0 1 0 0 0 RESISTANT TO H NEW 0 14 1 2 not on ART
89 1003012014 40 MALE 1.56 18.49 No Yes No 126 NEGATIVE 0 -SMEAR NEGATIVE 2-RESISTANT TO H ALONE No No No Yes No No No 1 0 0 0 0 0 RESISTANT TO H NEW 0 90 1 2 not on ART
90 455042013 40 MALE 1.66 16.3303818 No No No 308 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes No No Yes No No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 60 0 2 not on ART
91 2346102013 45 FEMAL
E
1.53 16.66 No Yes Yes 310 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No No No No Yes Yes Yes 1 0 1 0 0 1 SENSITIVE TO H ,R NEW 0 30 0 3 not on ART
92 2736092013 45 MALE 1.6 14.84 No No No 142 NEGATIVE 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes No No No No No 0 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
0 30 1 4 on ART
93 3868082009 40 MALE 1.68 15.94 No No No 299 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No No No Yes No No 0 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
1 5 0 4 on ART
94 3320122013 45 FEMAL
E
1.49 18.02 No Yes Yes 51 1+ 2- RESISTANT TO H ALONE 2-RESISTANT TO H ALONE No No Yes No No Yes No 1 0 0 0 0 1 RESISTANT TO H NEW 1 60 1 4 not on ART
95 2084052013 40 MALE 1.58 12.82 No Yes Yes 94 3+ 4 - MDR 4-MDR No Yes Yes No No No No 1 2 1 0 0 1 MDR RETREATMEN
T
1 90 1 7 not on ART
96 1502082013 41 MALE 1.64 12.64 No No No 123 2+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes Yes Yes Yes Yes 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 30 1 3 not on ART
97 1865012014 40 MALE 1.63 16.18 No No No 648 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes Yes Yes Yes Yes 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 20 0 2 not on ART
98 134082007 43 MALE 1.67 13.98 No No No 67 NEGATIVE 3- RESISTANT TO R ALONE 3-RESISTANT TO R ALONE Yes Yes No No No No No 0 2 1 1 0 0 RESISTANT TO R RETREATMEN
T
0 10 1 5 on ART
99 136112013 27 MALE 1.59 15.82 No No No 92 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No Yes No No Yes No No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 0 90 1 2 not on ART
100 1404082012 45 MALE 1.68 14.88 No No No 72 3+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No No Yes Yes Yes Yes 0 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
1 90 1 5 on ART
101 1749062013 24 MALE 1.55 20.4 No Yes Yes 164 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No No No No Yes No No 1 0 0 0 0 1 SENSITIVE TO H ,R NEW 0 120 1 3 not on ART
102 993012007 36 MALE 1.69 16.1058786 No No No 313 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes No No No No No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 30 0 2 not on ART
103 1592012013 30 MALE 1.62 17.1467764 No Yes Yes 39 1+ 2- RESISTANT TO H ALONE 2-RESISTANT TO H ALONE No No No No Yes No No 1 2 1 0 0 1 RESISTANT TO H RETREATMEN
T
1 120 1 7 on ART
104 3566012013 35 FEMAL
E
1.62 19.43 No No No 116 3+ 4 - MDR 4-MDR No No No Yes Yes No No 0 2 0 0 0 0 MDR RETREATMEN
T
1 180 1 4 on ART
105 638062013 35 MALE 1.72 12.17 No Yes Yes 111 2+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes No No Yes No No 1 0 1 0 0 1 SENSITIVE TO H ,R NEW 1 90 1 5 not on ART
106 2309082013 29 MALE 1.59 13.45 No No No 197 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R Yes Yes No No No No Yes 0 2 1 1 0 0 SENSITIVE TO H ,R RETREATMEN
T
1 90 1 6 on ART
107 2983092013 32 MALE 1.64 16.7311124 No No No 131 2+ 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No Yes Yes Yes No Yes Yes 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 10 1 3 not on ART
108 2284122013 40 MALE 1.65 12.86 No Yes Yes 258 NEGATIVE 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes Yes Yes Yes Yes 1 0 1 0 0 1 SENSITIVE TO H ,R NEW 0 60 0 3 on ART
109 2799122013 44 MALE 1.65 18.7327824 No Yes Yes 13 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No Yes No No Yes No 1 0 0 0 0 1 SENSITIVE TO H ,R NEW 1 20 1 4 not on ART
110 43012014 31 MALE 1.65 14.69 Yes No No 33 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes No No No Yes No 0 0 1 0 2 0 SENSITIVE TO H ,R NEW 1 120 1 5 not on ART
111 529122013 50 MALE 1.67 14.34 No No No 109 3+ 0 -SMEAR NEGATIVE 3-RESISTANT TO R ALONE No Yes No No Yes No No 0 0 1 0 0 0 RESISTANT TO R NEW 1 45 1 3 not on ART
112 1049022014 37 MALE 1.64 17.85 No No No 133 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes No Yes Yes No No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 14 1 3 on ART
113 320042013 35 MALE 1.59 15.8221589 No No No 244 3+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes No No Yes Yes Yes 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 90 0 2 not on ART
114 2400032014 43 MALE 1.65 15.79 No Yes No 159 NEGATIVE 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes Yes Yes Yes Yes 1 0 1 0 0 0 SENSITIVE TO H ,R NEW 0 60 1 3 not on ART
115 65042013 27 FEMAL
E
1.65 14.6923783 No No No 218 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No No No Yes No No No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 0 7 0 1 not on ART
116 4905062004 29 FEMAL
E
1.56 14.79 No No No 156 1+ 2- RESISTANT TO H ALONE 2-RESISTANT TO H ALONE No Yes No No No No No 0 2 1 0 0 0 RESISTANT TO H RETREATMEN
T
1 6 1 5 on ART
117 3499092003 45 MALE 1.63 18.07 No No No 235 NEGATIVE 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes Yes Yes Yes Yes 0 0 0 0 0 0 SENSITIVE TO H ,R NEW 0 90 0 0 on ART
118 1220082011 55 MALE 1.51 17.104513 No No No 514 3+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No Yes No No Yes No 0 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
1 14 0 4 not on ART
119 1594012014 58 MALE 1.56 16.4365549 No No No 694 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes No Yes Yes No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 14 0 2 not on ART
120 2514062013 30 MALE 1.49 18.47 No No No 512 NEGATIVE 3- RESISTANT TO R ALONE 3-RESISTANT TO R ALONE Yes No No No Yes No No 0 2 0 1 0 0 RESISTANT TO R RETREATMEN
T
0 90 0 3 not on ART
121 911072013 49 MALE 1.65 16.53 No No No 232 3+ 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No Yes No No Yes No No 0 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
1 365 0 4 not on ART
122 518102012 26 MALE 1.69 14.3552397 No Yes Yes 168 NEGATIVE 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No No No No No No 1 0 1 0 0 1 SENSITIVE TO H ,R NEW 0 30 1 4 on ART
123 4664082010 43 MALE 1.62 15.24 No No No 265 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes Yes Yes Yes Yes 0 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
1 20 0 4 not on ART
124 385032014 49 MALE 1.64 14.87 Yes No No 251 3+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R Yes No Yes Yes No Yes No 0 0 1 1 2 0 SENSITIVE TO H ,R NEW 1 180 0 5 not on ART
125 894012009 40 MALE 1.63 15.43 No Yes Yes 25 1+ 3- RESISTANT TO R ALONE 3-RESISTANT TO R ALONE No No No Yes Yes No No 1 0 1 0 0 1 RESISTANT TO R NEW 1 60 1 5 not on ART
126 966022014 32 MALE 1.67 15.78 No No No 230 3+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No No Yes Yes Yes No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 90 0 2 not on ART
127 3546012006 47 MALE 1.67 17.21 No No No 39 2+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No No No No No Yes 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 90 1 3 not on ART
128 2886082008 32 FEMAL
E
1.46 16.4195909 No No No 923 NEGATIVE 3- RESISTANT TO R ALONE 3-RESISTANT TO R ALONE No No Yes Yes No No No 0 2 1 0 0 0 RESISTANT TO R RETREATMEN
T
0 10 0 3 on ART
129 1040122012 36 MALE 1.57 17.44 No No No 42 3+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No No No Yes No No 0 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
1 60 1 5 on ART
130 2650052013 29 MALE 1.72 16.563007 No Yes Yes 85 NEGATIVE 0 -SMEAR NEGATIVE 4-MDR No No No No No No No 1 0 1 0 0 1 MDR NEW 0 14 1 4 not on ART
131 724062013 41 FEMAL
E
1.5 15.56 No Yes No 132 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No No Yes No No Yes No 1 0 1 0 0 0 SENSITIVE TO H ,R NEW 0 60 1 3 not on ART
132 1762072013 35 MALE 1.62 17.53 No No No 18 NEGATIVE 0 -SMEAR NEGATIVE 2-RESISTANT TO H ALONE No No No No No No Yes 0 2 1 0 0 0 RESISTANT TO H RETREATMEN
T
0 14 1 4 on ART
133 454042013 55 MALE 1.57 12.58 No No No 85 2+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes No No Yes No No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 180 1 3 not on ART
134 3466042013 55 FEMAL
E
1.58 14.02 No No No 109 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No No No No No No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 60 1 3 not on ART
135 3369122013 54 MALE 1.67 19.721037 No Yes Yes 124 NEGATIVE 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No No No No No No 1 0 0 0 0 1 SENSITIVE TO H ,R NEW 0 10 1 3 on ART
136 875052013 40 MALE 1.42 32.24 No No No 104 NEGATIVE 0 -SMEAR NEGATIVE 2-RESISTANT TO H ALONE No No No No Yes No No 0 2 0 0 0 0 RESISTANT TO H RETREATMEN
T
0 15 1 3 on ART
137 3.4081E+10 43 MALE 1.56 14.38 Yes No No 95 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No Yes No No No No 0 0 1 0 2 0 SENSITIVE TO H ,R NEW 1 60 1 5 not on ART
138 3245032013 33 MALE 1.59 13.8443891 No Yes Yes 75 3+ 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No No No No Yes No No 1 0 1 0 0 1 SENSITIVE TO H ,R NEW 1 120 1 5 not on ART
139 1132052013 35 MALE 1.55 15.4 Yes No No 199 1+ 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No No No No No Yes No 0 0 1 0 2 0 SENSITIVE TO H ,R NEW 1 3 1 5 on ART
140 527032009 40 MALE 1.67 15.78 No Yes No 269 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No No Yes No No Yes 1 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 15 0 3 on ART
141 2926062013 56 MALE 1.6 13.67 No No No 72 SCANTY 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R Yes Yes No No No No No 0 0 1 1 0 0 SENSITIVE TO H ,R NEW 1 90 1 4 not on ART
142 2206062006 42 MALE 1.62 19.0519738 No No No 341 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes Yes Yes Yes Yes 0 0 0 0 0 0 SENSITIVE TO H ,R NEW 1 0 1 not on ART
143 2709032014 40 MALE 1.7 15.92 No No No 102 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No Yes No No No No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 30 1 3 on ART
144 2917032013 39 MALE 1.58 16.82 No No No 166 3+ 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R Yes Yes No No No No No 0 0 1 1 0 0 SENSITIVE TO H ,R NEW 1 90 1 4 not on ART
145 475122013 38 MALE 1.61 13.89 No No No 107 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes No No No No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 365 1 3 not on ART
146 607122013 37 MALE 1.6 15.63 No No No 22 3+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No Yes No No Yes No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 30 1 3 on ART
147 113112013 25 MALE 1.74 19.1570881 No Yes Yes 178 NEGATIVE 0 -SMEAR NEGATIVE 4-MDR No No No Yes No No No 1 0 0 0 0 1 MDR NEW 0 30 1 3 not on ART
148 3666032013 45 MALE 1.61 15.43 No No No 94 SCANTY 0 -SMEAR NEGATIVE 4-MDR No Yes Yes No Yes Yes No 0 0 1 0 0 0 MDR NEW 1 180 1 3 not on ART
149 3636032013 42 MALE 1.58 20.03 No No No 20 3+ 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No No Yes No No No No 0 0 0 0 0 0 SENSITIVE TO H ,R NEW 1 30 1 2 not on ART
150 3368122013 44 MALE 1.7 20.07 No No No 335 2+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes No No Yes No No 0 0 0 0 0 0 SENSITIVE TO H ,R NEW 1 14 0 1 on ART
151 1638092009 45 MALE 1.7 10.38 No No No 111 3+ 4 - MDR 4-MDR No Yes Yes Yes Yes Yes No 0 2 1 0 0 0 MDR RETREATMEN
T
1 90 1 5 on ART
152 2498122013 41 MALE 1.52 15.148892 No Yes No 26 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No No Yes Yes No No 1 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 60 1 4 not on ART
153 2491012014 35 FEMAL
E
1.62 15.241579 No No No 246 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes No No Yes Yes No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 120 0 2 not on ART
154 3252072004 44 FEMAL
E
1.61 16.97 No No No 215 1+ 4 - MDR 4-MDR No No Yes No Yes No No 0 2 1 0 0 0 MDR RETREATMEN
T
1 30 0 4 on ART
155 3881062011 56 MALE 1.66 19.6 No No No 105 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No Yes No No No No No 0 0 0 0 0 0 SENSITIVE TO H ,R NEW 0 7 1 1 on ART
156 2345052013 34 MALE 1.68 14.17 Yes No No 215 2+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No No No Yes Yes No 0 0 1 0 2 0 SENSITIVE TO H ,R NEW 1 60 0 4 not on ART
157 464082013 38 MALE 1.67 12.91 No Yes Yes 120 1+ 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No No Yes Yes No No No 1 0 1 0 0 1 SENSITIVE TO H ,R NEW 1 10 1 5 not on ART
158 1135092103 41 MALE 1.6 13.67 No No No 254 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes Yes Yes Yes Yes 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 30 0 2 on ART
159 193022013 41 MALE 1.58 16.02 No No No 256 NEGATIVE 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes No No No No No 0 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
0 90 0 3 on ART
160 2598062013 38 MALE 1.6 15.63 No Yes No 234 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No No Yes Yes No No 1 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 90 0 3 not on ART
161 2715072013 45 FEMAL
E
1.48 13.7 No Yes No 265 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R Yes Yes No Yes Yes No No 1 2 1 1 0 0 SENSITIVE TO H ,R RETREATMEN
T
0 60 0 5 on ART
162 1984032014 26 MALE 1.64 13.01 No No No 123 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No No Yes No No Yes Yes 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 0 120 1 2 not on ART
163 1720092013 40 MALE 1.65 18.37 Yes No No 79 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No No No No Yes No No 0 0 0 0 2 0 SENSITIVE TO H ,R NEW 0 3 1 3 not on ART
164 379122013 38 MALE 1.6 13.67 No No No 119 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes No No Yes Yes No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 15 1 3 not on ART
165 1637052012 35 MALE 1.65 15.43 No No No 126 NEGATIVE 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No No Yes No No No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 0 5 1 2 on ART
166 1614072013 44 MALE 1.66 16.33 No No No 33 NEGATIVE 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes Yes Yes Yes Yes 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 0 14 1 2 on ART
167 2101042011 27 MALE 1.65 12.855831 No Yes Yes 123 2+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes No No No No 1 2 1 0 0 1 SENSITIVE TO H ,R RETREATMEN
T
1 15 1 7 on ART
168 1535062013 39 MALE 1.6 19.53 No No No 163 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No Yes Yes Yes Yes Yes Yes 0 0 0 0 0 0 SENSITIVE TO H ,R NEW 0 120 1 1 not on ART
169 1135032004 41 MALE 1.6 14.06 No No No 580 1+ 2- RESISTANT TO H ALONE 2-RESISTANT TO H ALONE No Yes Yes No No No No 0 2 1 0 0 0 RESISTANT TO H RETREATMEN
T
1 60 0 4 on ART
170 2323082009 31 MALE 1.54 15.6 No No No 87 NEGATIVE 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes No No No No No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 0 20 1 2 not on ART
171 1376062013 33 MALE 1.71 14.36 No No No 10 2+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No Yes No No No No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 180 1 3 on ART
172 3506112013 28 MALE 1.58 14.02 No No No 60 NEGATIVE 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes Yes Yes Yes Yes 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 0 45 1 2 not on ART
173 3240012014 26 MALE 1.56 14.79 No Yes Yes 58 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R Yes No No No Yes No No 1 0 1 1 0 1 SENSITIVE TO H ,R NEW 1 45 1 6 not on ART
174 1232122013 40 MALE 1.63 14.68 No No No 28 2+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes No No Yes No No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 7 1 3 not on ART
175 1071022014 40 MALE 1.63 16.18 No Yes Yes 37 NEGATIVE 2- RESISTANT TO H ALONE 2-RESISTANT TO H ALONE No No No Yes No No No 1 0 1 0 0 1 RESISTANT TO H NEW 0 30 1 4 not on ART
176 4555062007 37 MALE 1.6 17.58 No No No 241 2+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R Yes Yes No No Yes No No 0 2 1 1 0 0 SENSITIVE TO H ,R RETREATMEN
T
1 3 0 5 on ART
177 1281012004 40 MALE 1.6 13.67 No No No 28 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes Yes Yes Yes Yes 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 90 1 3 not on ART
178 2810032009 32 MALE 1.65 16.1616162 No No No 204 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No No No No No Yes 0 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
1 7 0 4 on ART
179 3862042009 49 MALE 1.68 17.7154195 No No No 391 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R Yes Yes No No No No No 0 0 1 1 0 0 SENSITIVE TO H ,R NEW 1 90 0 3 not on ART
180 346102013 45 MALE 1.55 13.32 No No No 331 NEGATIVE 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes Yes Yes Yes Yes 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 0 10 0 1 not on ART
181 82122013 52 MALE 1.55 15.82 No No No 298 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R Yes Yes Yes Yes Yes Yes Yes 0 0 1 1 0 0 SENSITIVE TO H ,R NEW 1 30 0 3 not on ART
182 5015042007 52 FEMAL
E
1.52 17.31 No No No 124 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No No No No No No No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 0 30 1 2 not on ART
183 2495012014 23 MALE 1.7 15.57 No Yes Yes 117 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No No No No No No No 1 0 1 0 0 1 SENSITIVE TO H ,R NEW 0 7 1 4 on ART
184 5799032006 46 MALE 1.68 14.17 No Yes Yes 132 3+ 4 - MDR 4-MDR No No Yes No No No No 1 2 1 0 0 1 MDR RETREATMEN
T
1 30 1 7 on ART
185 790092013 55 MALE 1.65 13.59 Yes Yes Yes 455 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes Yes Yes Yes Yes 1 0 1 0 2 1 SENSITIVE TO H ,R NEW 1 90 0 6 not on ART
186 3559032013 30 MALE 1.62 14.48 No No No 190 2+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes No Yes No No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 90 1 3 not on ART
187 2387022012 33 MALE 1.64 13.01 No No No 237 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R Yes No Yes No Yes Yes No 0 2 1 1 0 0 SENSITIVE TO H ,R RETREATMEN
T
1 7 0 5 on ART
188 1.2771E+10 41 MALE 1.62 16 No No No 255 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No Yes No No Yes No No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 0 7 0 1 not on ART
189 4311092004 40 MALE 1.68 14.17 No No No 180 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes Yes Yes Yes Yes 0 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
1 15 1 5 on ART
190 1893102012 40 MALE 1.69 14.71 No No No 175 3+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes Yes No No No 0 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
1 90 1 5 not on ART
191 2852082013 42 MALE 1.71 14.36 Yes No No 323 1+ 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No Yes No No Yes No No 0 0 1 0 2 0 SENSITIVE TO H ,R NEW 1 30 0 4 not on ART
192 3350102013 32 MALE 1.72 14.53 No No No 106 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No No Yes No No No No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 0 30 1 2 not on ART
193 4864082010 29 MALE 1.69 16.11 No No No 120 3+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes Yes Yes Yes No 0 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
1 15 1 5 on ART
194 224022014 37 MALE 1.43 21.52 No No No 61 2+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes No No No No No 0 0 0 0 0 0 SENSITIVE TO H ,R NEW 1 30 1 2 not on ART
195 856082010 36 MALE 1.8 13.89 No No No 122 1+ 2- RESISTANT TO H ALONE 2-RESISTANT TO H ALONE No No No No Yes No Yes 0 0 1 0 0 0 RESISTANT TO H NEW 1 30 1 3 on ART
196 1897092013 33 MALE 1.64 18.96 No No No 326 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No Yes No Yes Yes No 0 0 0 0 0 0 SENSITIVE TO H ,R NEW 1 7 0 1 not on ART
197 1456092013 47 MALE 1.62 15.24 No No No 334 3+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R Yes Yes Yes Yes Yes Yes No 0 0 1 1 0 0 SENSITIVE TO H ,R NEW 1 180 0 3 not on ART
198 3534052006 47 MALE 1.61 16.2 No No No 223 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes No No No No No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 30 0 2 not on ART
199 3895052006 44 MALE 1.61 13.5 No No No 289 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No No No No No No No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 0 3 0 1 on ART
200 3615022012 21 FEMAL
E
1.55 14.57 No Yes Yes 278 2+ 3- RESISTANT TO R ALONE 3-RESISTANT TO R ALONE No Yes No No Yes No No 1 2 1 0 0 1 RESISTANT TO R RETREATMEN
T
1 60 0 6 on ART
201 3670122013 44 MALE 1.72 20.96 No No No 16 3+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes Yes Yes Yes Yes 0 0 0 0 0 0 SENSITIVE TO H ,R NEW 1 60 1 2 not on ART
202 2879022014 55 MALE 1.7 17.99 No Yes No 348 2+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes No No Yes No Yes 1 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 180 0 3 not on ART
203 3185022014 45 MALE 1.59 15.031051 No No No 248 3+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes Yes Yes Yes Yes Yes 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 60 0 2 not on ART
204 150102013 33 FEMAL
E
1.54 16.87 No Yes Yes 152 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No No No Yes No No Yes 1 0 1 0 0 1 SENSITIVE TO H ,R NEW 0 30 1 4 not on ART
205 2487052013 45 MALE 1.64 17.1 No Yes Yes 38 SCANTY 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No No No Yes No No 1 2 1 0 0 1 SENSITIVE TO H ,R RETREATMEN
T
1 30 1 7 on ART
206 1238012014 32 MALE 1.65 14.69 No No No 57 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No No No No Yes No No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 0 60 1 2 not on ART
207 3705022014 41 MALE 1.59 13.84 No Yes Yes 180 NEGATIVE 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes No No No No No 1 0 1 0 0 1 SENSITIVE TO H ,R NEW 0 365 1 4 not on ART
208 1548032014 40 MALE 1.67 12.91 No No No 67 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No No No No Yes No No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 0 10 1 2 on ART
209 2267122013 42 MALE 1.72 19.27 No Yes No 92 NEGATIVE 0 -SMEAR NEGATIVE 3-RESISTANT TO R ALONE No No No No No No Yes 1 0 0 0 0 0 RESISTANT TO R NEW 0 90 1 2 not on ART
210 1878092013 49 MALE 1.67 15.059701 No No No 114 NEGATIVE 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes No No Yes No No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 0 30 1 2 on ART
211 3169052013 31 MALE 1.62 17.15 No No No 133 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No No No Yes No No No 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 0 60 1 2 not on ART
212 3132062013 45 FEMAL
E
1.49 15.77 No No No 42 NEGATIVE 0 -SMEAR NEGATIVE 3-RESISTANT TO R ALONE Yes No No Yes No No No 0 0 1 1 0 0 RESISTANT TO R NEW 0 30 1 3 not on ART
213 2230092013 46 MALE 1.61 17.3604413 No No No 127 1+ 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No Yes Yes Yes Yes Yes Yes 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 180 1 3 not on ART
214 1175092013 43 FEMAL
E
1.58 14.02 No No No 239 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No No Yes Yes No Yes Yes 0 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
0 30 0 3 on ART
215 1775062013 45 MALE 1.65 12.4885216 No No No 57 2+ 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No Yes No No No No Yes 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 1 120 1 3 not on ART
216 516112013 36 MALE 1.46 14.07 No No No 162 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No No No No No No Yes 0 0 1 0 0 0 SENSITIVE TO H ,R NEW 0 365 1 2 not on ART
217 1652062013 30 FEMAL
E
1.51 17.5430902 No Yes Yes 116 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No Yes No No No No No 1 0 1 0 0 1 SENSITIVE TO H ,R NEW 0 20 1 4 not on ART
218 3826032013 48 FEMAL
E
1.49 18.02 No No No 5 1+ 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No No No No No Yes No 0 0 0 0 0 0 SENSITIVE TO H ,R NEW 1 30 1 2 not on ART
219 1149032014 29 MALE 1.65 14.69 No No No 322 2+ 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No No Yes No No Yes No 0 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
1 21 0 4 on ART
220 1903022014 29 MALE 1.65 14.69 No Yes No 247 NEGATIVE 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No No No Yes No No 1 0 1 0 0 0 SENSITIVE TO H ,R NEW 0 60 0 2 on ART
221 2997022005 33 MALE 1.57 19.47 No No No 19 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No No No No No No 0 0 0 0 0 0 SENSITIVE TO H ,R NEW 1 90 1 2 not on ART
222 5113022009 28 MALE 1.62 19.81 No No No 18 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No Yes No No No No 0 0 0 0 0 0 SENSITIVE TO H ,R NEW 1 60 1 2 not on ART
223 195072005 47 MALE 1.7 18.69 No No No 593 2+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No Yes No No Yes No No 0 2 0 0 0 0 SENSITIVE TO H ,R RETREATMEN
T
1 7 0 3 on ART
224 2144082013 22 MALE 1.6 13.28 No No No 234 2+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R Yes Yes Yes No Yes Yes No 0 0 1 1 0 0 SENSITIVE TO H ,R NEW 1 15 0 3 not on ART
225 2374032014 33 FEMAL
E
1.46 18.3 No No No 24 NEGATIVE 0 -SMEAR NEGATIVE 1-SENSITIVE TO H & R No No No Yes No No Yes 0 0 0 0 0 0 SENSITIVE TO H ,R NEW 0 7 1 1 not on ART
226 2027052010 58 MALE 1.58 16.82 No Yes No 383 1+ 1- SENSITIVE TO H & R 1-SENSITIVE TO H & R No No No No No No Yes 1 2 1 0 0 0 SENSITIVE TO H ,R RETREATMEN
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